<?xml version="1.0" encoding="utf-8"?><dg:chunk cp:version="2.22.22.0.1705581103704-975.0" xmlns:docset="http://www.docugami.com/2021/dgml/docugami/ClinicalTrialProtocols" xmlns:addedChunks="http://www.docugami.com/2021/dgml/docugami/ClinicalTrialProtocols/addedChunks" xmlns:dg="http://www.docugami.com/2021/dgml" xmlns:dgc="http://www.docugami.com/2021/dgml/docugami/contracts" xmlns:dgm="http://www.docugami.com/2021/dgml/docugami/medical" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:cp="http://classifyprocess.com/2018/07/"><dg:chunk><docset:Protocol-section><dg:chunk structure="h1">

              Protocol: </dg:chunk><docset:Protocol structure="div">A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>Compared to <dgm:Medication>Humalog</dgm:Medication>® in Patients With T2DM </docset:Protocol></docset:Protocol-section><docset:NCT03341312Approved-section><dg:chunk structure="h1">

              <docset:ClinicalTrialID>NCT03341312 </docset:ClinicalTrialID>Approved: </dg:chunk><docset:NCT03341312Approved structure="div"><docset:Date>12</docset:Date>-<docset:Date>Dec-2017 </docset:Date></docset:NCT03341312Approved></docset:NCT03341312Approved-section></dg:chunk><dg:chunk><docset:Protocol18B-MC-ITRWB-section><dg:chunk structure="h1">

                                           Protocol 18B-MC-ITRW(b) </dg:chunk><docset:Protocol18B-MC-ITRWB structure="div">

                           A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog</dgm:Medication>® in </docset:Protocol18B-MC-ITRWB></docset:Protocol18B-MC-ITRWB-section><docset:PatientswithT2DM-section><dg:chunk structure="h1">

                                               Patients with T2DM </dg:chunk><xhtml:table structure="table" style="boundingBox:{left: 569; top: 628; width: 1412; height: 51; page: 2;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 569; top: 628; width: 1412; height: 51; page: 2;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 569; top: 628; width: 1412; height: 51; page: 2;}; "><xhtml:td structure="td" style="boundingBox:{left: 569; top: 628; width: 1412; height: 51; page: 2;}; "><docset:PatientswithT2DM>

                                                  EUDRACT: <docset:Year>2017</docset:Year>-<docset:EUDRACTNumber>001501</docset:EUDRACTNumber>-<docset:EUDRACTNumber>33 </docset:EUDRACTNumber>

                                                                                            | </docset:PatientswithT2DM></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:PatientswithT2DM-section></dg:chunk><docset:ConfidentialInformation-section><dg:chunk structure="h1">

                                            Confidential Information </dg:chunk><docset:ConfidentialInformation structure="div"><dg:chunk><docset:ConfidentialityAgreement structure="p">

                            The information contained in this protocol is confidential and is intended for the use of clinical investigators. It is the property of <dgc:Org><dg:chunk>Eli Lilly </dg:chunk>and Company </dgc:Org>or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of <docset:DrugName>LY900014</docset:DrugName>, unless such persons are bound by a confidentiality agreement with <docset:ConfidentialityAgreement><dg:chunk>Eli Lilly </dg:chunk>and Company </docset:ConfidentialityAgreement>or its subsidiaries. </docset:ConfidentialityAgreement><docset:NotetoRegulatoryAuthorities-section><dg:chunk structure="h1">

                            Note to <dg:chunk>Regulatory Authorities</dg:chunk>: </dg:chunk><docset:NotetoRegulatoryAuthorities structure="div">This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. <docset:ExemptDocument>Eli Lilly </docset:ExemptDocument>and Company requests consultation regarding release/redaction prior to any public release. In the <dg:chunk>United States</dg:chunk>, this document is subject to Freedom of Information Act (<dg:chunk>FOIA) Exemption </dg:chunk>4 and may not be reproduced or otherwise disseminated without the written </docset:NotetoRegulatoryAuthorities></docset:NotetoRegulatoryAuthorities-section></dg:chunk><docset:ApprovalofEliLillyAndCompanyOrItsSubsidiaries-section><dg:chunk structure="h1">

                            approval of <docset:CompanyName><dg:chunk>Eli Lilly </dg:chunk>and Company </docset:CompanyName>or its subsidiaries. </dg:chunk><docset:LY900014-section structure="div"><dg:chunk structure="h1">

                                                      <docset:LY900014>LY900014 </docset:LY900014></dg:chunk><docset:LY900014 structure="div"><dg:chunk><docset:CompanyAddress structure="p">

                                                <docset:CompanyName><dg:chunk>Eli Lilly </dg:chunk>and <dg:chunk>Company Indianapolis</dg:chunk></docset:CompanyName>, <dg:chunk><dgc:USState>Indiana </dgc:USState>USA </dg:chunk><docset:ZipCode>46285 </docset:ZipCode></docset:CompanyAddress><dg:chunk><docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly-secti><dg:chunk structure="h1">

                    <dg:chunk>Clinical Pharmacology Protocol </dg:chunk>Electronically Signed and Approved by <docset:ElectronicSignature>Lilly</docset:ElectronicSignature>: </dg:chunk><docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly structure="div">

                                                     <docset:AmendmentDate><dgc:Day>10 </dgc:Day><docset:AmendmentDate>Aug </docset:AmendmentDate><dgc:Year>2017 </dgc:Year></docset:AmendmentDate>Amendment (a) Electronically Signed and Approved by Lilly: 

                                                      <docset:AmendmentDate><docset:AmendmentDate>10 </docset:AmendmentDate><docset:AmendmentDate>Oct </docset:AmendmentDate><docset:AmendmentDate>2017 </docset:AmendmentDate></docset:AmendmentDate>Amendment (b) Electronically Signed and Approved by Lilly </docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly></docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly-secti><dg:chunk structure="p">

                                          on approval date provided below. </dg:chunk></dg:chunk></dg:chunk><docset:ApprovalDate-section><dg:chunk structure="h1">

                                                            <dg:chunk>Approval Date</dg:chunk>: </dg:chunk><docset:ApprovalDate structure="div"><dg:chunk structure="p"><docset:Date><docset:Date>12</docset:Date>-<docset:Date>Dec-2017 </docset:Date></docset:Date>GMT </dg:chunk><dg:chunk><dg:chunk structure="h1">

                                               Table of Contents </dg:chunk><dg:chunk structure="h1">

                         A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in </dg:chunk></dg:chunk></docset:ApprovalDate></docset:ApprovalDate-section></docset:LY900014></docset:LY900014-section></docset:ApprovalofEliLillyAndCompanyOrItsSubsidiaries-section></docset:ConfidentialInformation></docset:ConfidentialInformation-section><docset:PatientswithT2DM-section><dg:chunk structure="h1">

                                             Patients with T2DM </dg:chunk><docset:PatientswithT2DM structure="div"><dg:chunk><dg:chunk structure="h1">

              Section </dg:chunk><dg:chunk structure="h1">

                                                                                                    Page </dg:chunk></dg:chunk><docset:ProtocolI8B-MC-ITRWBAStudytoEvaluatethePharmacokineticsAnd-section><dg:chunk structure="h1">

              Protocol I8B-MC-ITRW(b) A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and </dg:chunk><docset:ProtocolI8B-MC-ITRWBAStudytoEvaluatethePharmacokineticsAnd structure="div"><dg:chunk structure="p">

                   Glucodynamics of <docset:DrugName>LY900014 </docset:DrugName>compared to <dgm:Medication>Humalog</dgm:Medication>® in Patients with T2DM </dg:chunk><docset:Main structure="p">

                                                                                                        <dgc:Number>1 </dgc:Number></docset:Main></docset:ProtocolI8B-MC-ITRWBAStudytoEvaluatethePharmacokineticsAnd></docset:ProtocolI8B-MC-ITRWBAStudytoEvaluatethePharmacokineticsAnd-section><docset:TableofContents-section><dg:chunk structure="h1">

              Table of Contents </dg:chunk><docset:TableofContents structure="div"><dg:chunk><docset:Main structure="p">

                                                                                                         <dgc:Number>2 </dgc:Number></docset:Main><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 296; top: 1055.0; width: 1954; height: 1727.0; page: 3;}; boundingBox:{left: 295; top: 874; width: 1952; height: 122; page: 4;}; "><dg:chunk structure="li" style="boundingBox:{left: 397; top: 1057; width: 1849; height: 54; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 304; top: 1053; width: 41; height: 50; page: 3;}; ">

              1. </dg:chunk><dg:chunk><dg:chunk>Protocol Synopsis</dg:chunk>. <docset:ProtocolSynopsis>8 </docset:ProtocolSynopsis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 398; top: 1135; width: 1848; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 297; top: 1137; width: 47; height: 47; page: 3;}; ">

              2. </dg:chunk><dg:chunk>Schedule of Activities <docset:ScheduleofActivities>11 </docset:ScheduleofActivities></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 399; top: 1220; width: 1845; height: 43; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 299; top: 1218; width: 40; height: 46; page: 3;}; ">

              3. </dg:chunk><dg:chunk>Introduction <docset:Introduction>18 </docset:Introduction></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 462; top: 1287; width: 1784; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 1287; width: 87; height: 47; page: 3;}; ">

               3.1. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Rationale </dg:chunk><docset:StudyRationale>18 </docset:StudyRationale></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 1356; width: 1785; height: 49; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 326; top: 1358; width: 67; height: 47; page: 3;}; ">

               3.2 </dg:chunk><dg:chunk structure="h1">Background <docset:Background>18 </docset:Background></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 461; top: 1427; width: 1783; height: 49; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1426; width: 88; height: 50; page: 3;}; ">

               3.3. </dg:chunk><dg:chunk>Benefit/Risk Assessment <docset:BenefitRiskAssessment>19 </docset:BenefitRiskAssessment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 396; top: 1507; width: 1849; height: 53; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 1507; width: 51; height: 49; page: 3;}; ">

              4. </dg:chunk><dg:chunk>Objectives and Endpoints <docset:ObjectivesandEndpoints>21 </docset:ObjectivesandEndpoints></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 398; top: 1589; width: 1851; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 304; top: 1587; width: 46; height: 54; page: 3;}; ">

              5. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk>... <docset:StudyDesign>22 </docset:StudyDesign></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 1659; width: 1788; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 1660; width: 89; height: 49; page: 3;}; ">

               5.1. </dg:chunk><dg:chunk><dg:chunk>Overall Design </dg:chunk><docset:OverallDesign>22 </docset:OverallDesign></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1729; width: 1789; height: 56; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 1728; width: 66; height: 50; page: 3;}; ">

                5.2 </dg:chunk><dg:chunk>Number of Participants <docset:NumberofParticipants>23 </docset:NumberofParticipants></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 462; top: 1798; width: 1785; height: 53; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 1800; width: 64; height: 47; page: 3;}; ">

                5.3 </dg:chunk><dg:chunk structure="p">End of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Definition </dg:chunk>.. <docset:EndofStudyDefinition>.24 </docset:EndofStudyDefinition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 466; top: 1870; width: 1781; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1872; width: 66; height: 45; page: 3;}; ">

               5.4 </dg:chunk><dg:chunk><dg:chunk>Scientific Rationale </dg:chunk>for <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk><docset:ScientificRationale>.24 </docset:ScientificRationale></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 398; top: 1936; width: 1848; height: 53; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1936; width: 67; height: 50; page: 3;}; ">

               5.5 </dg:chunk><dg:chunk>. Justification for Dose <docset:DoseJustification>24 </docset:DoseJustification></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 398; top: 2019; width: 1850; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 296; top: 2017; width: 56; height: 57; page: 3;}; ">

              6. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Population </dg:chunk><docset:StudyPopulation>25 </docset:StudyPopulation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 2091; width: 1790; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 2091; width: 90; height: 50; page: 3;}; ">

               6.1. </dg:chunk><dg:chunk><dg:chunk>Inclusion Criteria</dg:chunk>. <docset:InclusionCriteria>25 </docset:InclusionCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 2161; width: 1793; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 2161; width: 91; height: 51; page: 3;}; ">

               6.2. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Exclusion Criteria </dg:chunk><docset:ExclusionCriteria>27 </docset:ExclusionCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 2231; width: 1682; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 367; top: 2232; width: 131; height: 49; page: 3;}; ">

                 6.2.1. </dg:chunk><dg:chunk><dg:chunk>Additional Exclusion Criteria </dg:chunk>for <dg:chunk>Inpatient Dosing Days </dg:chunk><docset:AdditionalExclusionCriteria>.29 </docset:AdditionalExclusionCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 337; top: 2299; width: 1911; height: 331; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 2298; width: 85; height: 53; page: 3;}; ">

                6.3. </dg:chunk><dg:chunk><dg:chunk structure="p">Lifestyle and/or Dietary Requirements <docset:LifestyleandorDietaryRequirements>29 </docset:LifestyleandorDietaryRequirements></dg:chunk><docset:HealthandSafety structure="ol" style="list-style-type: decimal; boundingBox:{left: 337; top: 2372.0; width: 1911; height: 258.0; page: 3;}; "><dg:chunk structure="li" style="boundingBox:{left: 569; top: 2373; width: 1679; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2371; width: 122; height: 49; page: 3;}; ">

                  6.3.1. </dg:chunk><dg:chunk>Meals and <dg:chunk>Dietary Restrictions</dg:chunk>. <docset:MealsandDietaryRestrictions>30 </docset:MealsandDietaryRestrictions></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 2441; width: 1678; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 368; top: 2445; width: 117; height: 45; page: 3;}; ">

                 6.3.2. </dg:chunk><dg:chunk><dgm:Medication>Caffeine</dgm:Medication>, Alcohol, and Tobacco <docset:CaffeineAlcoholandTobacco>30 </docset:CaffeineAlcoholandTobacco></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 575; top: 2511; width: 1670; height: 56; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 2513; width: 116; height: 45; page: 3;}; ">

                 6.3.3. </dg:chunk><dg:chunk structure="p">Activity <docset:Activity30>30 </docset:Activity30></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 461; top: 2581; width: 1784; height: 48; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 337; top: 2583; width: 82; height: 47; page: 3;}; ">

                6.4. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Screen </dgm:_testRef>Failures </dg:chunk><docset:ScreenFailures>30 </docset:ScreenFailures></dg:chunk></dg:chunk></docset:HealthandSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 401; top: 2665; width: 1842; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300; top: 2663; width: 47; height: 50; page: 3;}; ">

              7. </dg:chunk><dg:chunk>Treatment <docset:Treatment>31 </docset:Treatment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 333; top: 2734; width: 1912; height: 250; page: 3;}; boundingBox:{left: 329; top: 302; width: 1919; height: 545; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 334; top: 2733; width: 82; height: 49; page: 3;}; ">

                7.1. </dg:chunk><dg:chunk><dg:chunk structure="p">Treatment Administered <docset:TreatmentAdministered>31 </docset:TreatmentAdministered></dg:chunk><docset:TreatmentProtocol structure="ol" style="list-style-type: decimal; boundingBox:{left: 333; top: 2807.0; width: 1296; height: 177.0; page: 3;}; boundingBox:{left: 329; top: 302; width: 1919; height: 545; page: 4;}; "><dg:chunk structure="li" style="boundingBox:{left: 376; top: 2807.0; width: 1873; height: 169.0; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 376; top: 2805; width: 108; height: 43; page: 3;}; ">

                  7.1.1. </dg:chunk><dg:chunk>Packaging and Labeling of <dg:chunk>Investigational Medicinal Product </dg:chunk>                                                                                                       <docset:PackagingandLabelingofInvestigationalMedicinalProduct>31 </docset:PackagingandLabelingofInvestigationalMedicinalProduct><docset:PackagingandLabelingRequirements>.32 </docset:PackagingandLabelingRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 333; top: 2933.0; width: 815.6; height: 51.0; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 333; top: 2930; width: 86; height: 49; page: 3;}; ">

                7.2. </dg:chunk><dg:chunk structure="h1">Method of <dg:chunk>Treatment Assignment </dg:chunk></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 562; top: 302; width: 1685; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 301; width: 117; height: 51; page: 4;}; ">

                  7.2.1. </dg:chunk><dg:chunk>Selection and Timing of Doses <docset:SelectionandTimingofDoses>32 </docset:SelectionandTimingofDoses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 373; width: 1786; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 372; width: 89; height: 51; page: 4;}; ">

                7.3. </dg:chunk><dg:chunk>Blinding <docset:BlindingSize>32 </docset:BlindingSize></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 442; width: 1785; height: 48; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 442; width: 64; height: 44; page: 4;}; ">

                7.4 </dg:chunk><dg:chunk><dg:chunk>Dose Modification </dg:chunk><docset:DoseModification>33 </docset:DoseModification></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 513; width: 1678; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 376; top: 513; width: 119; height: 50; page: 4;}; ">

                  7.4.1. </dg:chunk><dg:chunk><dg:chunk>Special Treatment Considerations </dg:chunk><docset:SpecialTreatmentConsiderations>33 </docset:SpecialTreatmentConsiderations></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 456; top: 583; width: 1792; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 582; width: 90; height: 50; page: 4;}; ">

               7.5. </dg:chunk><dg:chunk>Preparation/Handling/Storage/Accountability <docset:PreparationHandlingStorageAccountability>33 </docset:PreparationHandlingStorageAccountability></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 466; top: 654; width: 1780; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 653; width: 63; height: 45; page: 4;}; ">

                7.6 </dg:chunk><dg:chunk><dg:chunk>Treatment Compliance </dg:chunk><docset:TreatmentCompliance>34 </docset:TreatmentCompliance></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 721; width: 1785; height: 56; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 334; top: 723; width: 61; height: 44; page: 4;}; ">

                7.7 </dg:chunk><dg:chunk><dg:chunk>Concomitant Therapy </dg:chunk><docset:ConcomitantTherapy>34 </docset:ConcomitantTherapy></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 468; top: 794; width: 1780; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 334; top: 793; width: 73; height: 45; page: 4;}; ">

                7.8. </dg:chunk><dg:chunk>Treatment after the End of the <dgm:_testRef>Study </dgm:_testRef><docset:TreatmentAfterStudyEnd>35 </docset:TreatmentAfterStudyEnd></dg:chunk></dg:chunk></docset:TreatmentProtocol></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 395; top: 874; width: 1851; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295; top: 874; width: 51; height: 51; page: 4;}; ">

              8. </dg:chunk><dg:chunk><dg:chunk>Discontinuation Criteria </dg:chunk><docset:DiscontinuationCriteria>.36 </docset:DiscontinuationCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 298.0; top: 942; width: 1952.0; height: 2029; page: 4;}; boundingBox:{left: 297; top: 300; width: 1955; height: 2318; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 943; width: 90; height: 51; page: 4;}; ">

               8.1. </dg:chunk><dg:chunk><dg:chunk structure="p">Discontinuation from <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Treatment </dg:chunk><docset:DiscontinuationReason>.36 </docset:DiscontinuationReason></dg:chunk><docset:StudyAssessmentsandProcedures structure="ol" style="list-style-type: decimal; boundingBox:{left: 298.0; top: 1013; width: 1952.0; height: 1958; page: 4;}; boundingBox:{left: 297; top: 300; width: 1955; height: 2318; page: 5;}; "><dg:chunk structure="li" style="boundingBox:{left: 562; top: 1014; width: 1684; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 371; top: 1013; width: 125; height: 51; page: 4;}; ">

                 8.1.1. </dg:chunk><dg:chunk>Discontinuation of <dg:chunk>Inadvertently Enrolled Patients</dg:chunk>. <docset:DiscontinuationReason>36 </docset:DiscontinuationReason></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 1083; width: 1788; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1082; width: 89; height: 51; page: 4;}; ">

               8.2. </dg:chunk><dg:chunk>Discontinuation from the <dgm:_testRef>Study </dgm:_testRef><docset:StudyDiscontinuation>36 </docset:StudyDiscontinuation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1154; width: 1791; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 335; top: 1154; width: 81; height: 50; page: 4;}; ">

                8.3. </dg:chunk><dg:chunk>Patients Lost to Follow-up <docset:PatientsLosttoFollow-up>37 </docset:PatientsLosttoFollow-up></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 396; top: 1236; width: 1848; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 294; top: 1234; width: 52; height: 52; page: 4;}; ">

              9. </dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Assessments and Procedures <docset:StudyAssessmentsandProcedures>38 </docset:StudyAssessmentsandProcedures></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1306; width: 1787; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 1305; width: 88; height: 49; page: 4;}; ">

               9.1. </dg:chunk><dg:chunk>Efficacy Assessments <docset:EfficacyAssessments>38 </docset:EfficacyAssessments></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 1376; width: 1783; height: 49; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 324; top: 1375; width: 96; height: 50; page: 4;}; ">

               9.2. </dg:chunk><dg:chunk structure="h1">Visit Description <docset:Description>38 </docset:Description></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 1445; width: 1676; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 1444; width: 116; height: 51; page: 4;}; ">

                 9.2.1. </dg:chunk><dg:chunk><dg:chunk>Lead-In </dg:chunk>and <dg:chunk><dgm:Medication>Insulin </dgm:Medication>Transition </dg:chunk><docset:Lead-InandInsulinTransition>38 </docset:Lead-InandInsulinTransition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 569; top: 1518; width: 1675; height: 49; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 1516; width: 111; height: 48; page: 4;}; ">

                  9.2.2. </dg:chunk><dg:chunk><dg:chunk>Dose-Finding Assessment </dg:chunk><docset:Dose-FindingAssessment>39 </docset:Dose-FindingAssessment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 571; top: 1585; width: 1679; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 1587; width: 116; height: 44; page: 4;}; ">

                 9.2.3. </dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Period CRU Visits <docset:StudyPeriodCRUVisits>40 </docset:StudyPeriodCRUVisits></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 641; top: 1656; width: 1606; height: 46; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 406; top: 1657; width: 163; height: 46; page: 4;}; ">

                   9.2.3.1. </dg:chunk><dg:chunk>Run-In <docset:Run-InLength>40 </docset:Run-InLength></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 1723; width: 1610; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 406; top: 1727; width: 156; height: 47; page: 4;}; ">

                   9.2.3.2. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>MMTT </dg:chunk><docset:StudyMMTT40>40 </docset:StudyMMTT40></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 1796; width: 1782; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1795; width: 88; height: 48; page: 4;}; ">

               9.3. </dg:chunk><dg:chunk>Adverse Events <docset:AdverseEvents>40 </docset:AdverseEvents></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 1866; width: 1680; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 1866; width: 129; height: 49; page: 4;}; ">

                 9.3.1. </dg:chunk><dg:chunk><dg:chunk>Serious Adverse Events</dg:chunk>. <docset:SeriousAdverseEvents>41 </docset:SeriousAdverseEvents></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 1935; width: 1608; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 402; top: 1935; width: 171; height: 51; page: 4;}; ">

                   9.3.1.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Suspected Unexpected Serious Adverse Reactions </dg:chunk><docset:SuspectedUnexpectedSeriousAdverseReactions>42 </docset:SuspectedUnexpectedSeriousAdverseReactions></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 2007; width: 1683; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2005; width: 116; height: 50; page: 4;}; ">

                  9.3.2. </dg:chunk><dg:chunk><dg:chunk>Complaint Handling </dg:chunk><docset:ComplaintHandling>42 </docset:ComplaintHandling></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 462; top: 2078; width: 1786; height: 46; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 338; top: 2078; width: 81; height: 46; page: 4;}; ">

                9.4. </dg:chunk><dg:chunk>Treatment of Overdose <docset:TreatmentofOverdose>42 </docset:TreatmentofOverdose></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 2145; width: 1786; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 327; top: 2141; width: 93; height: 53; page: 4;}; ">

               9.5. </dg:chunk><dg:chunk>Safety <docset:Safety>43 </docset:Safety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 572; top: 2216; width: 1675; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 368; top: 2214; width: 131; height: 51; page: 4;}; ">

                 9.5.1. </dg:chunk><dg:chunk><dg:chunk>Physical <dgm:_testRef>Examination</dgm:_testRef></dg:chunk>. <docset:PhysicalExamination>43 </docset:PhysicalExamination></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 569; top: 2288; width: 1676; height: 48; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375; top: 2287; width: 110; height: 44; page: 4;}; ">

                  9.5.2. </dg:chunk><dg:chunk>Laboratory Tests <docset:LaboratoryTests>43 </docset:LaboratoryTests></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 572; top: 2355; width: 1673; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 2358; width: 113; height: 46; page: 4;}; ">

                 9.5.3. </dg:chunk><dg:chunk><dgm:MedicalTest>Vital Signs </dgm:MedicalTest><docset:VitalSigns>43 </docset:VitalSigns></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 2425; width: 1683; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2425; width: 111; height: 49; page: 4;}; ">

                  9.5.4. </dg:chunk><dg:chunk>Electrocardiograms <docset:Electrocardiograms>43 </docset:Electrocardiograms></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 2497; width: 1680; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 371; top: 2495; width: 128; height: 50; page: 4;}; ">

                 9.5.5. </dg:chunk><dg:chunk structure="p"><dg:chunk>Other Tests </dg:chunk>... ... <docset:OtherTests>44 </docset:OtherTests></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 647; top: 2566; width: 1603; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 411; top: 2570; width: 147; height: 44; page: 4;}; ">

                   9.5.5.1. </dg:chunk><dg:chunk>Hip and <dg:chunk>Waist Circumference </dg:chunk><docset:HipandWaistCircumference>44 </docset:HipandWaistCircumference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 2634; width: 1614; height: 56; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 407; top: 2635; width: 151; height: 47; page: 4;}; ">

                   9.5.5.2. </dg:chunk><dg:chunk><dg:chunk>Body Weight </dg:chunk>and <docset:Height><docset:Height>Height </docset:Height><docset:BodyWeightandHeight>44 </docset:BodyWeightandHeight></docset:Height></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 569; top: 2706; width: 1681; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 368; top: 2704; width: 132; height: 52; page: 4;}; ">

                 9.5.6. </dg:chunk><dg:chunk><dg:chunk>Safety Monitoring </dg:chunk><docset:SafetyMonitoring>44 </docset:SafetyMonitoring></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 644; top: 2775; width: 1606; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 406; top: 2777; width: 151; height: 47; page: 4;}; ">

                   9.5.6.1. </dg:chunk><dg:chunk><dg:chunk>Hepatic Safety </dg:chunk><docset:HepaticSafety>44 </docset:HepaticSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 645; top: 2843; width: 1605; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 2848; width: 153; height: 49; page: 4;}; ">

                   9.5.6.2. </dg:chunk><dg:chunk><dg:chunk>Glucose Monitoring </dg:chunk><docset:GlucoseMonitoring>45 </docset:GlucoseMonitoring></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 408.0; top: 2915.0; width: 684.0; height: 56.0; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 2913; width: 152; height: 51; page: 4;}; ">

                   9.5.6.3. </dg:chunk><dg:chunk>Severe <dgm:Condition>Hypoglycemia </dgm:Condition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 638; top: 300; width: 1612; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 302; width: 159; height: 50; page: 5;}; ">

                   9.5.6.4. </dg:chunk><dg:chunk><dg:chunk>Injection Site Assessments </dg:chunk>(<dg:chunk>Local Tolerability</dg:chunk>) <docset:InjectionSiteAssessments>46 </docset:InjectionSiteAssessments></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 572; top: 369; width: 1677; height: 59; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 376; top: 373; width: 113; height: 49; page: 5;}; ">

                  9.5.7. </dg:chunk><dg:chunk structure="p"><dg:chunk>Self-Monitored Plasma Glucose </dg:chunk>during <dg:chunk>Outpatient Period </dg:chunk><docset:Self-MonitoredPlasmaGlucoseduringOutpatientPeriod>.46 </docset:Self-MonitoredPlasmaGlucoseduringOutpatientPeriod></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 575; top: 442; width: 1672; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 440; width: 107; height: 46; page: 5;}; ">

                  9.5.8. </dg:chunk><dg:chunk>Treatment of Hyperglycemia and <dgm:Condition>Hypoglycemia </dgm:Condition><docset:TreatmentofHyperglycemiaandHypoglycem>.47 </docset:TreatmentofHyperglycemiaandHypoglycem></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 513; width: 1795; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 513; width: 92; height: 51; page: 5;}; ">

               9.6. </dg:chunk><dg:chunk><dg:chunk>Pharmacokinetics Samples </dg:chunk><docset:PharmacokineticsSamples>47 </docset:PharmacokineticsSamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 584; width: 1683; height: 49; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 582; width: 125; height: 48; page: 5;}; ">

                  9.6.1. </dg:chunk><dg:chunk>Bioanalysis <docset:Bioanalysis>47 </docset:Bioanalysis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 652; width: 1791; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 650; width: 89; height: 51; page: 5;}; ">

                9.7. </dg:chunk><dg:chunk>Pharmacodynamics <docset:Pharmacodynamics>47 </docset:Pharmacodynamics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 720; width: 1679; height: 56; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 371; top: 721; width: 120; height: 50; page: 5;}; ">

                 9.7.1. </dg:chunk><dg:chunk><dg:chunk>Glucodynamics Samples </dg:chunk><docset:GlucodynamicsSamples>48 </docset:GlucodynamicsSamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 642; top: 793; width: 1603; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 410; top: 792; width: 158; height: 48; page: 5;}; ">

                   9.7.1.1. </dg:chunk><dg:chunk><dg:chunk>Glucose Samples </dg:chunk>(<dg:chunk>Run-In Period</dg:chunk>) <docset:Run-InPeriodSamples>48 </docset:Run-InPeriodSamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 643; top: 861; width: 1608; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 864; width: 162; height: 49; page: 5;}; ">

                   9.7.1.2. </dg:chunk><dg:chunk><dg:chunk>Glucose Samples </dg:chunk>(MMTT) <docset:GlucoseSamples>48 </docset:GlucoseSamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 571; top: 930; width: 1674; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 366; top: 930; width: 119; height: 46; page: 5;}; ">

                 9.7.2. </dg:chunk><dg:chunk structure="p">Samples for <dg:chunk>Immunogenicity Assessments </dg:chunk><docset:ImmunogenicityAssaySamples>48 </docset:ImmunogenicityAssaySamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1003; width: 1787; height: 48; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 1001; width: 90; height: 50; page: 5;}; ">

               9.8. </dg:chunk><dg:chunk>Genetics <docset:Genetics>48 </docset:Genetics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 1073; width: 1789; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 325; top: 1072; width: 95; height: 51; page: 5;}; ">

               9.9. </dg:chunk><dg:chunk><dg:chunk>Exploratory Biomarkers </dg:chunk><docset:ExploratoryBiomarkers>49 </docset:ExploratoryBiomarkers></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1143; width: 1682; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 366; top: 1142; width: 134; height: 52; page: 5;}; ">

                 9.9.1. </dg:chunk><dg:chunk><dg:chunk>C-Peptide </dg:chunk>... <docset:C-Peptide>49 </docset:C-Peptide></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1212; width: 1790; height: 51; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1211; width: 115; height: 50; page: 5;}; ">

               9.10. </dg:chunk><dg:chunk><dg:chunk>Health Economics </dg:chunk><docset:HealthEconomics>49 </docset:HealthEconomics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 398; top: 1293; width: 1847; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 297; top: 1292; width: 78; height: 53; page: 5;}; ">

              10. </dg:chunk><dg:chunk><dg:chunk>Statistical Considerations </dg:chunk>and <dg:chunk>Data Analysis </dg:chunk><docset:StatisticalConsiderationsandDataAnalysis>50 </docset:StatisticalConsiderationsandDataAnalysis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1364; width: 1786; height: 51; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 1363; width: 112; height: 51; page: 5;}; ">

                10.1. </dg:chunk><dg:chunk><dg:chunk>Sample Size Determination </dg:chunk><docset:SampleSize>50 </docset:SampleSize></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 1432; width: 1789; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 334; top: 1432; width: 110; height: 54; page: 5;}; ">

                10.2. </dg:chunk><dg:chunk>Populations for Analyses <docset:PopulationsforAnalyses>50 </docset:PopulationsforAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1503; width: 1680; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 383; top: 1502; width: 144; height: 56; page: 5;}; ">

                  10.2.1. </dg:chunk><dg:chunk structure="p"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Participant Disposition </dg:chunk><docset:StudyParticipantDisposition>50 </docset:StudyParticipantDisposition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 1572; width: 1678; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 372; top: 1571; width: 152; height: 53; page: 5;}; ">

                 10.2.2. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Participant Characteristics </dg:chunk><docset:StudyParticipantCharacteristics>50 </docset:StudyParticipantCharacteristics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 1643; width: 1785; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 333; top: 1642; width: 112; height: 51; page: 5;}; ">

                10.3. </dg:chunk><dg:chunk><dg:chunk>Statistical Analyses </dg:chunk><docset:StatisticalAnalyses>50 </docset:StatisticalAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 1712; width: 1682; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 372; top: 1713; width: 149; height: 52; page: 5;}; ">

                 10.3.1. </dg:chunk><dg:chunk><dg:chunk>Safety Analyses</dg:chunk>. <docset:SafetyAnalyses>51 </docset:SafetyAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 1782; width: 1605; height: 59; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 1783; width: 188; height: 49; page: 5;}; ">

                   10.3.1.1. </dg:chunk><dg:chunk><dg:chunk>Clinical Evaluation </dg:chunk>of Safety <docset:ClinicalEvaluationofSafety>51 </docset:ClinicalEvaluationofSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 639; top: 1853; width: 1606; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 415; top: 1853; width: 184; height: 49; page: 5;}; ">

                   10.3.1.2. </dg:chunk><dg:chunk><dg:chunk>Statistical Evaluation </dg:chunk>of Safety <docset:StatisticalEvaluationofSafety>51 </docset:StatisticalEvaluationofSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 562; top: 1924; width: 1686; height: 50; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 1924; width: 151; height: 49; page: 5;}; ">

                  10.3.2. </dg:chunk><dg:chunk><dg:chunk>Pharmacokinetic Analyses </dg:chunk><docset:PharmacokineticAnalyses>51 </docset:PharmacokineticAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 635; top: 1990; width: 1610; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 408; top: 1994; width: 186; height: 49; page: 5;}; ">

                   10.3.2.1. </dg:chunk><dg:chunk><dg:chunk>Pharmacokinetic Parameter Estimation </dg:chunk><docset:PharmacokineticParameterEstimation>51 </docset:PharmacokineticParameterEstimation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 634; top: 2063; width: 1613; height: 50; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 414; top: 2062; width: 182; height: 49; page: 5;}; ">

                   10.3.2.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Pharmacokinetic Statistical Inference </dg:chunk><docset:PharmacokineticStatisticalInference>52 </docset:PharmacokineticStatisticalInference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 2135; width: 1682; height: 51; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 381; top: 2134; width: 139; height: 49; page: 5;}; ">

                  10.3.3. </dg:chunk><dg:chunk><dg:chunk><docset:GlucodynamicAnalysis>Glucodynamic </docset:GlucodynamicAnalysis>Analyses </dg:chunk><docset:GlucodynamicAnalyses>52 </docset:GlucodynamicAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 638; top: 2203; width: 1610; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 2202; width: 188; height: 52; page: 5;}; ">

                   10.3.3.1. </dg:chunk><dg:chunk><dg:chunk>Glucodynamic Parameter Estimation </dg:chunk><docset:GlucodynamicParameterEstimation>52 </docset:GlucodynamicParameterEstimation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 2271; width: 1607; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 413; top: 2272; width: 185; height: 52; page: 5;}; ">

                   10.3.3.2. </dg:chunk><dg:chunk><dg:chunk><docset:GlucodynamicStatisticalInference>Glucodynamic </docset:GlucodynamicStatisticalInference>Statistical Inference </dg:chunk><docset:GlucodynamicStatisticalInference>53 </docset:GlucodynamicStatisticalInference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 2344; width: 1682; height: 56; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375; top: 2341; width: 149; height: 51; page: 5;}; ">

                  10.3.4. </dg:chunk><dg:chunk>Evaluation of Immunogenicity <docset:ImmunogenicityEvaluation>53 </docset:ImmunogenicityEvaluation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 2413; width: 1682; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 382; top: 2415; width: 135; height: 49; page: 5;}; ">

                  10.3.5. </dg:chunk><dg:chunk><dg:chunk>C-Peptide </dg:chunk><docset:C-Peptide>53 </docset:C-Peptide></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 563; top: 2481; width: 1684; height: 56; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 383; top: 2485; width: 142; height: 45; page: 5;}; ">

                  10.3.6. </dg:chunk><dg:chunk><dg:chunk>Interim Analyses </dg:chunk><docset:InterimAnalyses>53 </docset:InterimAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 396; top: 2566; width: 1850; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 303; top: 2564; width: 69; height: 50; page: 5;}; ">

              11. </dg:chunk><dg:chunk>References <docset:References>54 </docset:References></dg:chunk></dg:chunk></docset:StudyAssessmentsandProcedures></dg:chunk></dg:chunk></docset:StudyDesign></dg:chunk><dg:chunk><docset:ListofTables-section><dg:chunk structure="h1">

                                                    List of Tables </dg:chunk><docset:ListofTables structure="div"><docset:ListofTables><xhtml:table structure="table" style="boundingBox:{left: 299.1; top: 372.3; width: 1950.9; height: 236.0; page: 6;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 299.1; top: 372.3; width: 1950.9; height: 236.0; page: 6;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 299.1; top: 372.3; width: 1950.9; height: 72.0; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.1; top: 372.3; width: 375.0; height: 72.0; page: 6;}; ">

              Table </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 674.0; top: 372.3; width: 1576.0; height: 72.0; page: 6;}; "><docset:Table>

                                                                                  Page </docset:Table></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.1; top: 444.3; width: 1950.9; height: 93.0; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.1; top: 444.3; width: 375.0; height: 93.0; page: 6;}; "><docset:Table>

              Table <docset:ITRW>ITRW.1</docset:ITRW>. </docset:Table></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 674.0; top: 444.3; width: 1576.0; height: 93.0; page: 6;}; "><docset:Page>

                  Objectives and Endpoints .......................................................................<docset:ObjectivesandEndpoints>21 </docset:ObjectivesandEndpoints></docset:Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.1; top: 537.3; width: 1950.9; height: 71.0; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.1; top: 537.3; width: 375.0; height: 71.0; page: 6;}; "><docset:Table>

              Table <docset:ITRW2>ITRW.2</docset:ITRW2>. </docset:Table></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 674.0; top: 537.3; width: 1576.0; height: 71.0; page: 6;}; "><docset:Page>

                  Treatments Administered........................................................................<docset:TreatmentsAdministered>31 </docset:TreatmentsAdministered></docset:Page></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofTables><docset:ListofFigures><xhtml:table structure="table" style="boundingBox:{left: 299.6; top: 312.5; width: 1950.4; height: 204.2; page: 7;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 299.6; top: 312.5; width: 1950.4; height: 204.2; page: 7;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 299.6; top: 312.5; width: 1950.4; height: 53.8; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.6; top: 312.5; width: 1950.4; height: 53.8; page: 7;}; " colspan="3"><dg:chunk structure="h1">

                                                    List of Figures </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.6; top: 366.3; width: 1950.4; height: 78.2; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.6; top: 366.3; width: 386.3; height: 78.2; page: 7;}; "><docset:ListofFiguresFigure>

              Figure </docset:ListofFiguresFigure></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 685.9; top: 366.3; width: 1193.2; height: 78.2; page: 7;}; "><docset:Figure /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1879.2; top: 366.3; width: 370.8; height: 78.2; page: 7;}; "><docset:Figure>

                          Page </docset:Figure></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.6; top: 444.5; width: 1950.4; height: 72.1; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.6; top: 444.5; width: 386.3; height: 72.1; page: 7;}; "><docset:ListofFiguresFigureITRW1>

              Figure ITRW.1. </docset:ListofFiguresFigureITRW1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 685.9; top: 444.5; width: 1193.2; height: 72.1; page: 7;}; "><docset:FigureITRW1 structure="p">

                 Illustration of <dgm:_testRef>study </dgm:_testRef>design for Protocol I8B-MC-ITRW. </docset:FigureITRW1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1879.2; top: 444.5; width: 370.8; height: 72.1; page: 7;}; "><docset:FigureITRW1>

              ........................<dgc:Number>22 </dgc:Number></docset:FigureITRW1></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofFigures></docset:ListofTables></docset:ListofTables-section><dg:chunk><dg:chunk structure="h1">

                                                 List of Appendices </dg:chunk><dg:chunk structure="div"><docset:ListofAppendices><xhtml:table structure="table" style="boundingBox:{left: 298.6; top: 371.2; width: 1951.4; height: 735.5; page: 8;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 298.6; top: 371.2; width: 1951.4; height: 735.5; page: 8;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 371.2; width: 1951.4; height: 73.7; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 371.2; width: 349.3; height: 73.7; page: 8;}; ">

              Appendix </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 371.2; width: 710.4; height: 73.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1358.3; top: 371.2; width: 560.4; height: 73.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1918.8; top: 371.2; width: 114.6; height: 73.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2033.3; top: 371.2; width: 90.1; height: 73.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2123.4; top: 371.2; width: 126.6; height: 73.7; page: 8;}; ">

              Page </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 444.9; width: 1951.4; height: 92.6; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 444.9; width: 349.3; height: 92.6; page: 8;}; "><docset:AppendixAppendix1>

              Appendix 1. </docset:AppendixAppendix1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 444.9; width: 710.4; height: 92.6; page: 8;}; "><docset:Appendix1>

                   Abbreviations and Definitions </docset:Appendix1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1358.3; top: 444.9; width: 891.7; height: 92.6; page: 8;}; " colspan="4"><docset:Appendix1>

              ................................................................<dgc:Number>55 </dgc:Number></docset:Appendix1></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 537.5; width: 1951.4; height: 91.7; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 537.5; width: 349.3; height: 91.7; page: 8;}; "><docset:AppendixAppendix2>

              Appendix <docset:Appendix2>2</docset:Appendix2>. </docset:AppendixAppendix2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 537.5; width: 710.4; height: 91.7; page: 8;}; "><docset:Appendix2>

                   <dg:chunk>Clinical Laboratory </dg:chunk></docset:Appendix2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1358.3; top: 537.5; width: 560.4; height: 91.7; page: 8;}; "><docset:Appendix2>

    Tests........................................................................<docset:Texts>59 </docset:Texts></docset:Appendix2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1918.8; top: 537.5; width: 114.6; height: 91.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2033.3; top: 537.5; width: 90.1; height: 91.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2123.4; top: 537.5; width: 126.6; height: 91.7; page: 8;}; "><docset:Appendix2Page /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 629.2; width: 1951.4; height: 94.3; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 629.2; width: 349.3; height: 94.3; page: 8;}; "><docset:AppendixAppendix3>

              Appendix 3. </docset:AppendixAppendix3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 629.2; width: 1270.8; height: 94.3; page: 8;}; " colspan="2"><docset:Appendix3 structure="p">

                   <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Governance</dg:chunk>, Regulatory and Ethical Considerations </docset:Appendix3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1918.8; top: 629.2; width: 331.2; height: 94.3; page: 8;}; " colspan="3"><docset:Appendix3>

              .....................<dgc:Number>60 </dgc:Number></docset:Appendix3></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 723.5; width: 1951.4; height: 93.1; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 723.5; width: 349.3; height: 93.1; page: 8;}; "><docset:AppendixAppendix4>

              Appendix 4. </docset:AppendixAppendix4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 723.5; width: 1385.4; height: 93.1; page: 8;}; " colspan="3"><docset:Appendix4 structure="h1">

                   <dg:chunk>Hepatic Monitoring Tests </dg:chunk>for <dg:chunk>Treatment-Emergent Abnormality </dg:chunk></docset:Appendix4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2033.3; top: 723.5; width: 216.7; height: 93.1; page: 8;}; " colspan="2"><docset:Appendix4>

              ............<dgc:Number>63 </dgc:Number></docset:Appendix4></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 816.7; width: 1951.4; height: 91.7; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 816.7; width: 349.3; height: 91.7; page: 8;}; "><docset:AppendixAppendix5>

              Appendix 5. </docset:AppendixAppendix5></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 816.7; width: 710.4; height: 91.7; page: 8;}; "><docset:Appendix5>

                   <dgm:MedicalTest>Blood Sampling </dgm:MedicalTest></docset:Appendix5></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1358.3; top: 816.7; width: 560.4; height: 91.7; page: 8;}; "><docset:Appendix5>

 Summary......................................................................<docset:Summary>64 </docset:Summary></docset:Appendix5></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1918.8; top: 816.7; width: 114.6; height: 91.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2033.3; top: 816.7; width: 90.1; height: 91.7; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2123.4; top: 816.7; width: 126.6; height: 91.7; page: 8;}; "><docset:Appendix5Page /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.6; top: 908.3; width: 1951.4; height: 198.4; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.6; top: 908.3; width: 349.3; height: 198.4; page: 8;}; "><docset:AppendixAppendix6>

              Appendix <docset:Appendix6>6</docset:Appendix6>. </docset:AppendixAppendix6></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 647.9; top: 908.3; width: 1475.5; height: 198.4; page: 8;}; " colspan="4"><docset:Appendix6 structure="p">

                   Protocol Amendment I8B-MC-ITRW(b) Summary: A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrugName>LY900014 </docset:StudyDrugName>compared to <dgm:Medication>Humalog</dgm:Medication>® in Patients with T2DM .....................................<docset:StudySummary>65 </docset:StudySummary></docset:Appendix6></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2123.4; top: 908.3; width: 126.6; height: 198.4; page: 8;}; "><docset:Appendix6 /></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofAppendices><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 941.7; top: 308.3; width: 662.5; height: 66.7; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 941.7; top: 308.3; width: 662.5; height: 66.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 941.7; top: 308.3; width: 58.3; height: 66.7; page: 9;}; ">

                                            1. </dg:chunk><dg:chunk>Protocol Synopsis </dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk></docset:TableofContents></docset:TableofContents-section><dg:chunk><dg:chunk structure="h1">

              Title of <dgm:_testRef>Study</dgm:_testRef>: </dg:chunk><dg:chunk structure="div">

              A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in Patients with T2DM </dg:chunk></dg:chunk><dg:chunk><docset:Rationale-section><dg:chunk structure="h1">

              Rationale: </dg:chunk><docset:Rationale structure="div"><docset:InsulinLisproFormulation structure="p">

              <docset:InsulinLisproFormulation>LY900014 </docset:InsulinLisproFormulation>is an ultra-rapid acting <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation with increased early absorption compared to commercially available <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation (<docset:ComparatorDrug>Humalog, <dg:chunk>Eli Lilly</dg:chunk>)</docset:ComparatorDrug>. <dg:chunk>LY900014 </dg:chunk>aims to mimic the physiological prandial <dgm:Medication>insulin </dgm:Medication>secretion pattern, which may more effectively control postprandial glucose excursions and allow increased flexibility of the time of dosing relative to a meal. </docset:InsulinLisproFormulation><docset:StudyObjectives structure="p">

              The aim of this <dgm:_testRef>study </dgm:_testRef>is to compare the <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>pharmacokinetic (PK), glucodynamic (GD), and tolerability profiles of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following administration of either <docset:StudyAim>LY900014 </docset:StudyAim>or <dgm:Medication>Humalog </dgm:Medication>during a mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>(MMTT) in patients with type 2 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>(T2DM). </docset:StudyObjectives></docset:Rationale></docset:Rationale-section><docset:ObjectivesEndpoints-section><dg:chunk structure="h1">

              Objectives/Endpoints: </dg:chunk><docset:ObjectivesEndpoints structure="div"><docset:ProtocolSynopsis><xhtml:table structure="table" style="boundingBox:{left: 301.0; top: 1288.8; width: 1946.0; height: 962.0; page: 9;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 301.0; top: 1288.8; width: 1946.0; height: 962.0; page: 9;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 301.0; top: 1288.8; width: 1946.0; height: 98.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 301.0; top: 1288.8; width: 974.0; height: 98.0; page: 9;}; "><dg:chunk structure="h1">

               Objectives </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1275.0; top: 1288.8; width: 972.0; height: 98.0; page: 9;}; "><docset:Objectives structure="h1">

               Endpoints </docset:Objectives></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 301.0; top: 1387.8; width: 1946.0; height: 314.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 301.0; top: 1386.8; width: 974.0; height: 315.0; page: 9;}; "><docset:Primary-section><dg:chunk structure="h1">

               Primary </dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 320.8; top: 1504.2; width: 904.2; height: 166.7; page: 9;}; "><docset:Primary structure="li" style="boundingBox:{left: 320.8; top: 1504.2; width: 904.2; height: 166.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 320.8; top: 1504.2; width: 33.3; height: 41.7; page: 9;}; ">

               1. </dg:chunk><dg:chunk>To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC injection of <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>in patients with T2DM. </dg:chunk></docset:Primary></dg:chunk></docset:Primary-section></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1275.0; top: 1386.8; width: 972.0; height: 315.0; page: 9;}; "><docset:Endpoints structure="h1">

               <docset:EarlyAUC>1</docset:EarlyAUC>. Early <docset:EarlyTmax>50% </docset:EarlyTmax>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </docset:Endpoints></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 301.0; top: 1702.8; width: 1946.0; height: 548.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 301.0; top: 1701.8; width: 974.0; height: 549.0; page: 9;}; "><docset:Objectives><dg:chunk structure="h1">

               Secondary </dg:chunk><docset:StudyObjectives structure="ol" style="list-style-type: decimal; boundingBox:{left: 320.8; top: 1820.8; width: 916.7; height: 387.5; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 320.8; top: 1820.8; width: 916.7; height: 291.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 320.8; top: 1820.8; width: 33.3; height: 41.7; page: 9;}; ">

               1. </dg:chunk><dg:chunk>To evaluate the effect of injection-to-meal timings (immediately before the start of meal, and <docset:Injection-to-MealTiming>20 minutes </docset:Injection-to-MealTiming>following the start of the meal) on the GD response to <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog</dgm:Medication>, as measured by the <docset:MealToleranceTest>MMTT</docset:MealToleranceTest>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 321.0; top: 2166.7; width: 770.7; height: 41.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 320.8; top: 2166.7; width: 33.3; height: 41.7; page: 9;}; ">

               2. </dg:chunk><dg:chunk>To evaluate the tolerability of <docset:DrugName>LY900014</docset:DrugName>. </dg:chunk></dg:chunk></docset:StudyObjectives></docset:Objectives></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1275.0; top: 1701.8; width: 972.0; height: 549.0; page: 9;}; "><docset:Endpoints structure="ol" style="list-style-type: decimal; boundingBox:{left: 1295.8; top: 1820.8; width: 583.3; height: 387.5; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 1295.8; top: 1820.8; width: 554.2; height: 42.5; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1295.8; top: 1820.8; width: 29.2; height: 45.8; page: 9;}; ">

               1. </dg:chunk><dg:chunk structure="p"><dgc:Number>∆AUC(0</dgc:Number>-<docset:_2-HourAUC>2hr</docset:_2-HourAUC>), <docset:AUCChange>∆AUC(0</docset:AUCChange>-<docset:AUCat5Hours>5hr</docset:AUCat5Hours>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 1295.8; top: 2166.7; width: 583.3; height: 41.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1295.8; top: 2166.7; width: 29.2; height: 41.7; page: 9;}; ">

               2. </dg:chunk><dg:chunk>AEs and hypoglycemic events </dg:chunk></dg:chunk></docset:Endpoints></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ProtocolSynopsis><docset:Abbreviations-section><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><docset:Abbreviations structure="div">AE = adverse event; <docset:AreaUndertheCurve>AUC(0</docset:AreaUndertheCurve>-<docset:MaximumTime>30min</docset:MaximumTime>) = area under the concentration versus time curve (AUC) from 

                time zero to <docset:TimeFrame>30 minutes</docset:TimeFrame>; ∆AUC = area under the baseline subtracted glucose concentration versus time curve; early <docset:Percentage>50% </docset:Percentage>tmax = time to early half-maximal drug concentration; GD = glucodynamics; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; PK = pharmacokinetics; SC = subcutaneous; T2DM = type 2 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus</dgm:Condition>. </docset:Abbreviations></docset:Abbreviations-section></docset:ObjectivesEndpoints></docset:ObjectivesEndpoints-section></dg:chunk><docset:SummaryofStudyDesign-section><dg:chunk structure="h1">

              Summary of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design</dg:chunk>: </dg:chunk><docset:SummaryofStudyDesign structure="div">

              <dgm:_testRef>Study </dgm:_testRef>I8B-MC-ITRW is a Phase 1, randomized, patient and investigator blind, <docset:StudyDescription>2</docset:StudyDescription>-treatment, <docset:StudyDescription>4</docset:StudyDescription>-period crossover <dgm:_testRef>study </dgm:_testRef>to evaluate meal to dose-timing in patients with T2DM. </docset:SummaryofStudyDesign></docset:SummaryofStudyDesign-section><docset:TreatmentArmsAndPlannedDurationforanIndividualPatient-section><dg:chunk structure="h1">

              <dg:chunk>Treatment Arms </dg:chunk>and <dg:chunk>Planned Duration </dg:chunk>for an Individual patient: </dg:chunk><docset:TreatmentArmsAndPlannedDurationforanIndividualPatient structure="div">

              Patients will be screened over a <docset:ScreeningPeriod>14-day </docset:ScreeningPeriod>period prior to start of an approximate <docset:Lead-inPeriod>2-week </docset:Lead-inPeriod>lead-in/<dgm:Medication>insulin </dgm:Medication>transition period. Patients will then participate in a dose-finding assessment (Day <dg:chunk>-1 </dg:chunk>of Period <dgc:Number>1</dgc:Number>) and subsequently randomised to <docset:StudyPeriods>1 </docset:StudyPeriods>of <docset:StudyPeriods>4 </docset:StudyPeriods>treatment sequences according to the actual randomization table provided to the site. In each <dgm:_testRef>study </dgm:_testRef>period, patients will undergo an MMTT. Each patient will receive a single subcutaneous injection of either <docset:StudyDrug>LY900014 </docset:StudyDrug>or <dgm:Medication>Humalog </dgm:Medication>either immediately before the <dgm:_testRef>test </dgm:_testRef>meal or <docset:StudyDuration>20 minutes </docset:StudyDuration>following the start of the <dgm:_testRef>test </dgm:_testRef>meal. All treatment procedures will be inpatient stays of approximately <docset:StudyDuration>2 days </docset:StudyDuration>per period and require a maximum of <docset:StudyDuration>6 weeks </docset:StudyDuration>to complete <dgc:TimeDuration>4 </dgc:TimeDuration>periods. Each <dgm:_testRef>study </dgm:_testRef>dosing will be separated by a minimum of <docset:StudyDosingSeparation>21 hours </docset:StudyDosingSeparation>and may occur on consecutive visits, however patient inclusion is subject to required <dgm:_testRef>screening </dgm:_testRef>criteria. The follow-up or early discontinuation visit should occur at least <docset:ScreeningPeriod>14 days </docset:ScreeningPeriod>after the last dose of the <dgm:_testRef>study </dgm:_testRef>drug. </docset:TreatmentArmsAndPlannedDurationforanIndividualPatient></docset:TreatmentArmsAndPlannedDurationforanIndividualPatient-section><dg:chunk structure="h1">

              Treatment: </dg:chunk><dg:chunk><dg:chunk structure="h1">

              <docset:LY900014>LY900014</docset:LY900014>: </dg:chunk><dg:chunk structure="div">Single individualized SC dose per assessment period </dg:chunk></dg:chunk><docset:Humalog-section><dg:chunk structure="h1">

              <dgm:Medication>Humalog</dgm:Medication>: </dg:chunk><docset:Humalog structure="div">Single individualized SC dose per assessment period </docset:Humalog></docset:Humalog-section><docset:NumberofPatients-section><dg:chunk structure="h1">

              Number of Patients: </dg:chunk><docset:NumberofPatients structure="div">Up to <docset:MaximumNumberofPatients>36 </docset:MaximumNumberofPatients>patients may be enrolled to ensure that at least <docset:NumberofPatients>30 </docset:NumberofPatients>patients will complete the <dgm:_testRef>study</dgm:_testRef>. <docset:MaximumNumberofPatients>Thirty </docset:MaximumNumberofPatients>completing patients will provide greater than <docset:PowerCalculation>95% </docset:PowerCalculation>power to demonstrate a <docset:StudyEnrollment>2</docset:StudyEnrollment>-<docset:PowerCalculation>fold </docset:PowerCalculation>increase in the serum <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication><docset:SerumInsulinAUC>AUC(0-</docset:SerumInsulinAUC><docset:SerumInsulinAUC>30min</docset:SerumInsulinAUC>) between <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>when both are given immediately before meals. </docset:NumberofPatients></docset:NumberofPatients-section><docset:StatisticalAnalysis-section><dg:chunk structure="h1">

              <dg:chunk>Statistical Analysis</dg:chunk>: </dg:chunk><docset:StatisticalAnalysis structure="div"><docset:StudyDesign structure="p">Primary statistical analyses of PK and GD parameters will be conducted on the set of patients who complete all treatment periods. Supportive analyses may be done on the key parameters for the patients who complete at least the first period of treatment. Safety analyses will be conducted on the set of patients receiving at least <docset:StatisticalAnalysis>1 </docset:StatisticalAnalysis>dose of the <dgm:_testRef>study </dgm:_testRef>drug to which they are randomized, regardless of whether or not they complete all protocol requirements. </docset:StudyDesign><docset:StatisticalAnalysis structure="p">

              Unless otherwise noted, all tests of treatment effects will be conducted at a <docset:TreatmentEffectsTests>2</docset:TreatmentEffectsTests>-sided <dgm:Medication>alpha </dgm:Medication>level of <docset:AlphaLevel>0.05</docset:AlphaLevel>, and confidence intervals (CIs) will be calculated at <docset:ConfidenceInterval>95%</docset:ConfidenceInterval>, 2-sided. </docset:StatisticalAnalysis></docset:StatisticalAnalysis></docset:StatisticalAnalysis-section><docset:Safety-section><dg:chunk structure="h1">

              Safety: </dg:chunk><docset:Safety structure="div">All investigational product and protocol procedure AEs will be listed, and if the frequency of events allows, safety data will be summarized using descriptive methodology. Safety parameters will be listed and summarized using standard descriptive statistics. </docset:Safety></docset:Safety-section><docset:Pharmacokinetic-section><dg:chunk structure="h1">

              Pharmacokinetic: </dg:chunk><docset:Pharmacokinetic structure="div"><docset:StatisticalAnalysis structure="p">Log-transformed AUCs, Cmax, CL/F and Vz/F for <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>will be evaluated to estimate geometric means, ratios of geometric means of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>within <docset:TreatmentGroup>LY900014 </docset:TreatmentGroup>to <dgm:Medication>Humalog</dgm:Medication>, and the corresponding <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs of the ratios using the mixed-effects model that includes treatment and period as fixed effects and patient as a random effect. </docset:StatisticalAnalysis><docset:StatisticalAnalysis structure="p">

              The same model without log transformation will be used for the analysis of the PK time parameters (early <docset:Percentage>50% </docset:Percentage>tmax, late <dgc:Percent>50% </dgc:Percent>tmax, tmax, and t1/2). Least-squares means (LSmeans), treatment differences in LSmeans, and the corresponding <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs for the treatment differences will be estimated from the model. The p-value on the difference between LS means will be used to determine statistical significance. The treatment ratios and <dgc:Percent>95% </dgc:Percent>CIs for the ratios will be calculated using <docset:FiellersTheorem>Fieller</docset:FiellersTheorem>’s theorem. </docset:StatisticalAnalysis></docset:Pharmacokinetic></docset:Pharmacokinetic-section><docset:Glucodynamic-section><dg:chunk structure="h1">

              Glucodynamic: </dg:chunk><docset:Glucodynamic structure="div"><docset:StudyDesign structure="p">Data will be analyzed for the patients during each MMTT. The change from baseline values (the average of <docset:BaselineGlucoseConcentration>-30</docset:BaselineGlucoseConcentration>, <docset:BaselineSubtractedGlucoseConcentration>-15</docset:BaselineSubtractedGlucoseConcentration>, and <docset:BaselineSubtractedGlucoseArea>0 minutes</docset:BaselineSubtractedGlucoseArea>) represented as the <docset:BaselineSubtractedGlucoseAreaUndertheCurve>0</docset:BaselineSubtractedGlucoseAreaUndertheCurve>-<docset:Time>hour </docset:Time>time point following the start of the MMTT for each patient will be calculated. The area under the baseline subtracted glucose concentration versus time curve from time </docset:StudyDesign><dg:chunk><docset:GlucoseAUC structure="p">

              <docset:AUC0-2h>0 </docset:AUC0-2h>to <docset:_2hrAUC>2hr </docset:_2hrAUC>(<docset:AUCArea>∆AUC[0</docset:AUCArea>-<docset:_2-HourAUC>2h</docset:_2-HourAUC>]) and area under the baseline subtracted glucose concentration versus time curve from time </docset:GlucoseAUC><dg:chunk><docset:GlucoseMetabolismEndpoints structure="p">

              <docset:Post-MealGlucoseMetrics>0 </docset:Post-MealGlucoseMetrics>to <docset:Post-MealAUC>5hr </docset:Post-MealAUC>post meal (<docset:Post-MealAUC>∆AUC[0</docset:Post-MealAUC>-5h]) will be calculated. In addition, the change from baseline maximum glucose observed during the <docset:Post-MealAUC>5 hours </docset:Post-MealAUC>postmeal and change from baseline <docset:Post-MealGlucoseAUC>1</docset:Post-MealGlucoseAUC>-hour glucose and <docset:Post-MealGlucoseMetrics>2</docset:Post-MealGlucoseMetrics>-<docset:Post-MealTime>hour </docset:Post-MealTime><docset:GlucoseAUC>glucose </docset:GlucoseAUC>post the start of the meal will be calculated. Other partial ∆AUCs may be calculated as deemed appropriate. </docset:GlucoseMetabolismEndpoints><dg:chunk><docset:StatisticalAnalysis structure="p">

              Summary statistics will be presented by treatment and by timing of dose (all 4 combinations of treatment and timing of dose). The GD parameters on the original scale will be analyzed using the mixed-effects model that includes treatment, timing of dose, treatment-by-timing of dose interaction, and period as fixed effects and patient as a random effect. </docset:StatisticalAnalysis><dg:chunk><docset:StatisticalAnalysis structure="p">

              The p-value on the difference between LS means will be used to determine statistical significance and the corresponding <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs for the LS Mean ratios from <docset:FiellersTheorem>Fieller</docset:FiellersTheorem>’s theorem will be presented. </docset:StatisticalAnalysis><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 887.5; top: 308.3; width: 770.8; height: 66.7; page: 12;}; "><dg:chunk structure="li" style="boundingBox:{left: 887.5; top: 308.3; width: 770.8; height: 66.7; page: 12;}; "><dg:chunk structure="lim" style="boundingBox:{left: 887.5; top: 308.3; width: 58.3; height: 66.7; page: 12;}; ">

                                          2. </dg:chunk><dg:chunk>Schedule of Activities </dg:chunk></dg:chunk></dg:chunk><docset:SignInformedConsentScreeningLead-inStudyPeriod><xhtml:table structure="table" style="boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1490.0; page: 13;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1792.0; page: 14;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1152.0; page: 15;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1792.0; page: 16;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1796.0; page: 17;}; boundingBox:{left: 299.9; top: 355.0; width: 2738.0; height: 657.0; page: 18;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1490.0; page: 13;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1792.0; page: 14;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1152.0; page: 15;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1792.0; page: 16;}; boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 1796.0; page: 17;}; boundingBox:{left: 299.9; top: 355.0; width: 2738.0; height: 657.0; page: 18;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 355.0; width: 2738.0; height: 165.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 355.0; width: 456.0; height: 165.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 355.0; width: 258.0; height: 165.0; page: 13;}; "><dg:chunk structure="h1">

                  <dg:chunk>Sign Informed Consent </dg:chunk></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 355.0; width: 224.0; height: 165.0; page: 13;}; "><dg:chunk structure="h1">

               <dgm:_testRef>Screening </dgm:_testRef></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 355.0; width: 282.0; height: 165.0; page: 13;}; "><dg:chunk structure="h1">

                 Lead-in </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 355.0; width: 592.0; height: 165.0; page: 13;}; " colspan="2"><dg:chunk structure="h1">

                <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Period </dg:chunk>(Periods <docset:StudyPeriod>1 </docset:StudyPeriod>to <docset:StudyPeriod>4</docset:StudyPeriod>) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 355.0; width: 320.0; height: 165.0; page: 13;}; "><dg:chunk structure="h1">

                  Follow- up/Early discontinuation </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 355.0; width: 606.0; height: 165.0; page: 13;}; ">

                        Comments </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 521.0; width: 2738.0; height: 109.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 520.0; width: 456.0; height: 110.0; page: 13;}; "><dg:chunk structure="h1">

               Procedure </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 520.0; width: 258.0; height: 110.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 520.0; width: 224.0; height: 110.0; page: 13;}; "><docset:Screening>

                Days <docset:DaysBeforeDeparture>-30 </docset:DaysBeforeDeparture>to <docset:DaysBeforeDeparture>-17 </docset:DaysBeforeDeparture></docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 520.0; width: 282.0; height: 110.0; page: 13;}; "><docset:Lead-in structure="h1">

               <docset:DaysPriortoDay-2>14 days </docset:DaysPriortoDay-2>prior to Day <docset:Day-2>-2 </docset:Day-2></docset:Lead-in></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 520.0; width: 236.0; height: 110.0; page: 13;}; "><docset:ProcedureStudyPeriodPeriods1to4>

                 Day <docset:DayBefore>-1 </docset:DayBefore></docset:ProcedureStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 520.0; width: 356.0; height: 110.0; page: 13;}; "><docset:ProcedureFollow-UpEarlyDiscontinuation>

                    Day <docset:Day1>1 </docset:Day1></docset:ProcedureFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 520.0; width: 320.0; height: 110.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation>

               <docset:DischargeDate>≥14 days </docset:DischargeDate>after discharge </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 520.0; width: 606.0; height: 110.0; page: 13;}; "><docset:Comments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 631.0; width: 2738.0; height: 325.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 630.0; width: 456.0; height: 326.0; page: 13;}; ">

               <dg:chunk>Informed Consent </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 630.0; width: 258.0; height: 326.0; page: 13;}; "><docset:SignInformedConsent>

                   X </docset:SignInformedConsent></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 630.0; width: 224.0; height: 326.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 630.0; width: 282.0; height: 326.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 630.0; width: 236.0; height: 326.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 630.0; width: 356.0; height: 326.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 630.0; width: 320.0; height: 326.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 630.0; width: 606.0; height: 326.0; page: 13;}; "><docset:Comments structure="p">

               At least <docset:ScreeningProceduresDeadline>1 day </docset:ScreeningProceduresDeadline>before <dgm:_testRef>screening </dgm:_testRef>procedures. <dgm:_testRef>Screening </dgm:_testRef>procedures should take place no later than <docset:ScreeningProceduresDeadline>28 days </docset:ScreeningProceduresDeadline>after signing the informed consent (see Section <docset:ScreeningProceduresDeadline>9.5.2</docset:ScreeningProceduresDeadline>). </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 957.0; width: 2738.0; height: 109.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 956.0; width: 456.0; height: 110.0; page: 13;}; "><dg:chunk structure="h1">

               Medical history and physical <dgm:_testRef>examination </dgm:_testRef></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 956.0; width: 258.0; height: 110.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 956.0; width: 224.0; height: 110.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 956.0; width: 282.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 956.0; width: 236.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 956.0; width: 356.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 956.0; width: 320.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 956.0; width: 606.0; height: 110.0; page: 13;}; "><docset:Comments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1067.0; width: 2738.0; height: 109.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1066.0; width: 456.0; height: 110.0; page: 13;}; ">

               Hip and waist circumference </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1066.0; width: 258.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1066.0; width: 224.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1066.0; width: 282.0; height: 110.0; page: 13;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1066.0; width: 236.0; height: 110.0; page: 13;}; "><docset:HipAndWaistCircumferenceStudyPeriodPeriods1to4>

                   X </docset:HipAndWaistCircumferenceStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1066.0; width: 356.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1066.0; width: 320.0; height: 110.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1066.0; width: 606.0; height: 110.0; page: 13;}; "><docset:Comments>

               Period 1 only. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1177.0; width: 2738.0; height: 61.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1176.0; width: 456.0; height: 62.0; page: 13;}; ">

               Height </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1176.0; width: 258.0; height: 62.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1176.0; width: 224.0; height: 62.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1176.0; width: 282.0; height: 62.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1176.0; width: 236.0; height: 62.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1176.0; width: 356.0; height: 62.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1176.0; width: 320.0; height: 62.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1176.0; width: 606.0; height: 62.0; page: 13;}; "><docset:Comments>

               At <dgm:_testRef>screening </dgm:_testRef>only </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1239.0; width: 2738.0; height: 60.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1238.0; width: 456.0; height: 61.0; page: 13;}; ">

               Weight </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1238.0; width: 258.0; height: 61.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1238.0; width: 224.0; height: 61.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1238.0; width: 282.0; height: 61.0; page: 13;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1238.0; width: 236.0; height: 61.0; page: 13;}; "><docset:WeightStudyPeriodPeriods1to4>

                   X </docset:WeightStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1238.0; width: 356.0; height: 61.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1238.0; width: 320.0; height: 61.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1238.0; width: 606.0; height: 61.0; page: 13;}; "><docset:Comments>

               Period 1 only. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1300.0; width: 2738.0; height: 163.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1299.0; width: 456.0; height: 164.0; page: 13;}; "><dg:chunk structure="p">

               <dgm:MedicalTest>Vital signs</dgm:MedicalTest>: blood pressure and pulse rate </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1299.0; width: 258.0; height: 164.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1299.0; width: 224.0; height: 164.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1299.0; width: 282.0; height: 164.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1299.0; width: 236.0; height: 164.0; page: 13;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1299.0; width: 356.0; height: 164.0; page: 13;}; "><docset:VitalSignsBloodPressureAndPulseRateFollow-UpEarlyDiscontinuation structure="h1">

                Predose, <docset:PostdoseTimepoint>30 </docset:PostdoseTimepoint>and <docset:PostdoseTime>120 minutes </docset:PostdoseTime>postdose </docset:VitalSignsBloodPressureAndPulseRateFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1299.0; width: 320.0; height: 164.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1299.0; width: 606.0; height: 164.0; page: 13;}; "><docset:Comments structure="p">

               <dgm:MedicalTest>Vital signs </dgm:MedicalTest>will be taken while patients are supine at <dgm:_testRef>screening </dgm:_testRef>and semi-supine on Day 1. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1464.0; width: 2738.0; height: 109.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1463.0; width: 456.0; height: 110.0; page: 13;}; ">

               <docset:NumberofLeads>12</docset:NumberofLeads>-lead <dgm:MedicalTest>ECG </dgm:MedicalTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1463.0; width: 258.0; height: 110.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1463.0; width: 224.0; height: 110.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1463.0; width: 282.0; height: 110.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1463.0; width: 236.0; height: 110.0; page: 13;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1463.0; width: 356.0; height: 110.0; page: 13;}; "><docset:_12-leadECGFollow-UpEarlyDiscontinuation>

                   Predose (Period <docset:Predose>1</docset:Predose>) </docset:_12-leadECGFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1463.0; width: 320.0; height: 110.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1463.0; width: 606.0; height: 110.0; page: 13;}; "><docset:Comments structure="p">

               Single ECGs will be collected for safety. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1574.0; width: 2738.0; height: 271.0; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1573.0; width: 456.0; height: 272.0; page: 13;}; ">

               Clinical laboratory tests </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1573.0; width: 258.0; height: 272.0; page: 13;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1573.0; width: 224.0; height: 272.0; page: 13;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1573.0; width: 282.0; height: 272.0; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1573.0; width: 236.0; height: 272.0; page: 13;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1573.0; width: 356.0; height: 272.0; page: 13;}; "><docset:ClinicalLaboratoryTestsFollow-UpEarlyDiscontinuation structure="h1">

                  Predose for Period <docset:Predose>1 </docset:Predose>only </docset:ClinicalLaboratoryTestsFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1573.0; width: 320.0; height: 272.0; page: 13;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1573.0; width: 606.0; height: 272.0; page: 13;}; "><docset:Comments structure="p">

               Fasting laboratory <dgm:_testRef>test </dgm:_testRef>for <dgm:_testRef>screening </dgm:_testRef>and follow-up. <dgm:_testRef>Screening </dgm:_testRef>laboratory tests will be analyzed at a local laboratory (see Section <docset:LaboratoryTestAnalysisLocation>9.5.2</docset:LaboratoryTestAnalysisLocation>). </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 631.0; width: 2738.0; height: 702.0; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 630.0; width: 456.0; height: 703.0; page: 14;}; ">

               Lead-in/<dgm:Medication>insulin </dgm:Medication>transition activities </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 630.0; width: 258.0; height: 703.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 630.0; width: 224.0; height: 703.0; page: 14;}; "><docset:Screening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 630.0; width: 282.0; height: 703.0; page: 14;}; "><docset:Lead-in>

                X (Period 1 only) </docset:Lead-in></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 630.0; width: 236.0; height: 703.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 630.0; width: 356.0; height: 703.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 630.0; width: 320.0; height: 703.0; page: 14;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 630.0; width: 606.0; height: 703.0; page: 14;}; "><docset:Comments><docset:InsulinSwitching structure="p">

               Once patients have completed <dgm:_testRef>screening </dgm:_testRef>procedures, switch from prescribed short-acting and basal <dgm:Medication>insulin </dgm:Medication>to site-provided <dgm:Medication>Humalog </dgm:Medication>and <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine </dgm:Medication>respectively. Patients receive general <dgm:Condition>diabetes </dgm:Condition>training. A patient diary will be provided for recording dosing and other required information (Section </docset:InsulinSwitching><docset:Lead-inPeriod structure="p">

               <docset:Lead-inPeriod>9.2.1</docset:Lead-inPeriod>). Lead-in period may be extended by <docset:Lead-inPeriod>2 days </docset:Lead-inPeriod>(eg, <docset:Lead-inPeriod>16 days </docset:Lead-inPeriod>prior to Day <docset:Lead-inPeriod>-2</docset:Lead-inPeriod>) as needed. </docset:Lead-inPeriod></docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1334.0; width: 2738.0; height: 271.0; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1333.0; width: 456.0; height: 272.0; page: 14;}; ">

               Patient admission to <docset:CRUAdmission>CRU </docset:CRUAdmission></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1333.0; width: 258.0; height: 272.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1333.0; width: 224.0; height: 272.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1333.0; width: 282.0; height: 272.0; page: 14;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1333.0; width: 236.0; height: 272.0; page: 14;}; "><docset:PatientAdmissiontoCRUStudyPeriodPeriods1to4>

                   X </docset:PatientAdmissiontoCRUStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1333.0; width: 356.0; height: 272.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1333.0; width: 320.0; height: 272.0; page: 14;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1333.0; width: 606.0; height: 272.0; page: 14;}; "><docset:Comments structure="p">

               Admitted to CRU evening Day - <dgc:Number>2 </dgc:Number>or early morning Day <docset:AdmissionDate>-1 </docset:AdmissionDate>(Period 1 only). For Periods <docset:AdmissionDate>2 </docset:AdmissionDate>– <docset:AdmissionDate>4</docset:AdmissionDate>, patients may be admitted evening of Day <dgc:Number>-1</dgc:Number>. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1606.0; width: 2738.0; height: 541.0; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1605.0; width: 456.0; height: 542.0; page: 14;}; ">

               Dose-finding </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1605.0; width: 258.0; height: 542.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1605.0; width: 224.0; height: 542.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1605.0; width: 282.0; height: 542.0; page: 14;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1605.0; width: 236.0; height: 542.0; page: 14;}; "><docset:Dose-findingStudyPeriodPeriods1to4>

                   X (Period 1 only) </docset:Dose-findingStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1605.0; width: 356.0; height: 542.0; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1605.0; width: 320.0; height: 542.0; page: 14;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1605.0; width: 606.0; height: 542.0; page: 14;}; "><docset:Comments structure="p">

               Following <dgm:Medication>insulin </dgm:Medication>transition patients will undergo dose- finding with <dgm:Medication>Humalog </dgm:Medication>and a <dgm:_testRef>test </dgm:_testRef>meal. To take place between <docset:TestMealTime>07:00 </docset:TestMealTime>and <docset:TestMealEndTime>11:00</docset:TestMealEndTime>. Blood glucose concentrations will be monitored every <docset:BloodGlucoseMonitoringInterval>20 minutes </docset:BloodGlucoseMonitoringInterval>for <docset:TestMealDuration>5 hours </docset:TestMealDuration>postmeal (see Section 9.2.2). See Section <docset:Rescheduling>6.2.1 </docset:Rescheduling>for rescheduling. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 631.0; width: 2738.0; height: 109.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 630.0; width: 456.0; height: 110.0; page: 15;}; ">

               Randomization </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 630.0; width: 258.0; height: 110.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 630.0; width: 224.0; height: 110.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 630.0; width: 282.0; height: 110.0; page: 15;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 630.0; width: 236.0; height: 110.0; page: 15;}; "><docset:RandomizationStudyPeriodPeriods1to4>

                   X </docset:RandomizationStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 630.0; width: 356.0; height: 110.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 630.0; width: 320.0; height: 110.0; page: 15;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 630.0; width: 606.0; height: 110.0; page: 15;}; "><docset:Comments structure="p">

               To take place before run-in of Period <docset:Run-InDate>1 </docset:Run-InDate>Day <dgc:Number>1</dgc:Number>. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 741.0; width: 2738.0; height: 325.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 740.0; width: 456.0; height: 326.0; page: 15;}; ">

               <dgm:MedicalTest><dgm:Condition>Pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 740.0; width: 258.0; height: 326.0; page: 15;}; "><docset:SignInformedConsent /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 740.0; width: 224.0; height: 326.0; page: 15;}; "><docset:Screening>

                   X </docset:Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 740.0; width: 282.0; height: 326.0; page: 15;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 740.0; width: 236.0; height: 326.0; page: 15;}; "><docset:PregnancyTestStudyPeriodPeriods1to4>

                   X </docset:PregnancyTestStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 740.0; width: 356.0; height: 326.0; page: 15;}; "><docset:PregnancyTestFollow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 740.0; width: 320.0; height: 326.0; page: 15;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 740.0; width: 606.0; height: 326.0; page: 15;}; "><docset:Comments><docset:PregnancyTesting structure="p">

               Serum <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>will be performed at <dgm:_testRef>screening </dgm:_testRef>and urine <dgm:Condition>pregnancy </dgm:Condition>tests will be performed at admission for Period 1 and at follow-up (see </docset:PregnancyTesting><dg:chunk structure="p">

               Appendix <docset:FieldName>2</docset:FieldName>). </dg:chunk></docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1067.0; width: 2738.0; height: 61.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1066.0; width: 456.0; height: 62.0; page: 15;}; ">

               Standard dinner </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1066.0; width: 258.0; height: 62.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1066.0; width: 224.0; height: 62.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1066.0; width: 282.0; height: 62.0; page: 15;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1066.0; width: 236.0; height: 62.0; page: 15;}; "><docset:StandardDinnerStudyPeriodPeriods1to4>

                   X </docset:StandardDinnerStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1066.0; width: 356.0; height: 62.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1066.0; width: 320.0; height: 62.0; page: 15;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1066.0; width: 606.0; height: 62.0; page: 15;}; "><docset:Comments>

               Approximately <docset:StartTime>19:00 </docset:StartTime></docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1129.0; width: 2738.0; height: 378.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1128.0; width: 456.0; height: 379.0; page: 15;}; ">

               Medical assessment </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1128.0; width: 258.0; height: 379.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1128.0; width: 224.0; height: 379.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1128.0; width: 282.0; height: 379.0; page: 15;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1128.0; width: 236.0; height: 379.0; page: 15;}; "><docset:MedicalAssessmentStudyPeriodPeriods1to4>

                   X </docset:MedicalAssessmentStudyPeriodPeriods1to4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1128.0; width: 356.0; height: 379.0; page: 15;}; "><docset:MedicalAssessmentFollow-UpEarlyDiscontinuation structure="h1">

                  Predose and before discharge from <docset:CRUDischargeDate>CRU </docset:CRUDischargeDate></docset:MedicalAssessmentFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1128.0; width: 320.0; height: 379.0; page: 15;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1128.0; width: 606.0; height: 379.0; page: 15;}; "><docset:Comments structure="p">

               Medical assessment includes medical review, and targeted <dgm:_testRef>examination</dgm:_testRef>, and as appropriate, review of concomitant medication, patient diary and MMTT exclusion criteria (see Section <dg:chunk>6.2.1</dg:chunk>). </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 631.0; width: 2738.0; height: 648.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 630.0; width: 456.0; height: 649.0; page: 16;}; ">

               Glucose stabilization/run-in </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 630.0; width: 258.0; height: 649.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 630.0; width: 224.0; height: 649.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 630.0; width: 282.0; height: 649.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 630.0; width: 236.0; height: 649.0; page: 16;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 630.0; width: 356.0; height: 649.0; page: 16;}; "><docset:GlucoseStabilizationRun-inFollow-UpEarlyDiscontinuation>

                      X </docset:GlucoseStabilizationRun-inFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 630.0; width: 320.0; height: 649.0; page: 16;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 630.0; width: 606.0; height: 649.0; page: 16;}; "><docset:Comments><docset:GlucoseInfusion structure="p">

               From approximately <docset:GlucoseInfusionStartTime>7 hours </docset:GlucoseInfusionStartTime>to <docset:BloodGlucoseMonitoringInterval>30 minutes </docset:BloodGlucoseMonitoringInterval>before dosing: infusion of glucose (<dgm:Medication>dextrose </dgm:Medication>solution) or <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glulisine </dgm:Medication>to achieve a target blood glucose concentration of <docset:TargetBloodGlucoseConcentration>135 </docset:TargetBloodGlucoseConcentration><docset:BloodGlucoseConcentrationTolerance>±15 </docset:BloodGlucoseConcentrationTolerance>mg/dL (<docset:TargetBloodGlucoseConcentration><docset:TargetBloodGlucoseConcentration>7.5 </docset:TargetBloodGlucoseConcentration>±0.8 mmol</docset:TargetBloodGlucoseConcentration>/L). Blood glucose concentrations will be monitored at a minimum of <docset:BloodGlucoseMonitoringInterval>30-minute </docset:BloodGlucoseMonitoringInterval>intervals (see Section </docset:GlucoseInfusion><dg:chunk><dg:chunk structure="p">

               <docset:FieldName>9.2.3.1 </docset:FieldName>and <docset:FieldName>9.7.1.1</docset:FieldName>). See Section </dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 2450.0; top: 1237.5; width: 379.2; height: 41.7; page: 16;}; "><dg:chunk structure="li" style="boundingBox:{left: 2450.0; top: 1237.5; width: 379.2; height: 41.7; page: 16;}; "><dg:chunk structure="lim" style="boundingBox:{left: 2450.0; top: 1237.5; width: 87.5; height: 41.7; page: 16;}; ">

               6.2.1 </dg:chunk><dg:chunk>for rescheduling. </dg:chunk></dg:chunk></dg:chunk></dg:chunk></docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1280.0; width: 2738.0; height: 487.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1279.0; width: 456.0; height: 488.0; page: 16;}; ">

               Blood glucose sampling (MMTT) </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1279.0; width: 258.0; height: 488.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1279.0; width: 224.0; height: 488.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1279.0; width: 282.0; height: 488.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1279.0; width: 236.0; height: 488.0; page: 16;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1279.0; width: 356.0; height: 488.0; page: 16;}; "><docset:BloodGlucoseSamplingMMTTFollow-UpEarlyDiscontinuation structure="p">

                  <docset:Pre-MealTime>-30</docset:Pre-MealTime>, <docset:Pre-MealTime>-15</docset:Pre-MealTime>, <docset:MealTime>0 </docset:MealTime>minutes pre-meal, <docset:Post-MealTime>10</docset:Post-MealTime>, <docset:Post-MealTime>20</docset:Post-MealTime>, <docset:Post-MealTimeIntervals>30</docset:Post-MealTimeIntervals>, <docset:Post-MealTime>40</docset:Post-MealTime>, <docset:Post-MealTime>50</docset:Post-MealTime>, <docset:Post-MealTimeIntervals>60</docset:Post-MealTimeIntervals>, <docset:Post-MealTime>70</docset:Post-MealTime>, <docset:Post-MealTime>80</docset:Post-MealTime>, <docset:Post-MealTime>90</docset:Post-MealTime>, <docset:MealTime>100</docset:MealTime>, <docset:Post-MealTime>110</docset:Post-MealTime>, <docset:Post-MealTime>120</docset:Post-MealTime>, <docset:Post-MealTime>135</docset:Post-MealTime>, <docset:Post-MealTime>150</docset:Post-MealTime>, <docset:Post-MealTime>165</docset:Post-MealTime>, <docset:Post-MealTime>180</docset:Post-MealTime>, <docset:Post-MealTime>195</docset:Post-MealTime>, <docset:Post-MealTime>210</docset:Post-MealTime>, <docset:Post-MealTime>225</docset:Post-MealTime>, <docset:Post-MealTime>240</docset:Post-MealTime>, <docset:Post-MealTime>300 </docset:Post-MealTime>minutes post-meal </docset:BloodGlucoseSamplingMMTTFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1279.0; width: 320.0; height: 488.0; page: 16;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1279.0; width: 606.0; height: 488.0; page: 16;}; "><docset:Comments structure="p">

               <docset:StartTimeSample>0</docset:StartTimeSample>-<docset:StartTime>minute </docset:StartTime>time point sample to be taken at the start of the meal. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1768.0; width: 2738.0; height: 379.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1767.0; width: 456.0; height: 380.0; page: 16;}; "><dg:chunk structure="h1">

               Mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>(<docset:MixedMealToleranceTest>MMTT</docset:MixedMealToleranceTest>) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1767.0; width: 258.0; height: 380.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1767.0; width: 224.0; height: 380.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1767.0; width: 282.0; height: 380.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1767.0; width: 236.0; height: 380.0; page: 16;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1767.0; width: 356.0; height: 380.0; page: 16;}; "><docset:MixedMealToleranceTestMMTTFollow-UpEarlyDiscontinuation>

                      X </docset:MixedMealToleranceTestMMTTFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1767.0; width: 320.0; height: 380.0; page: 16;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1767.0; width: 606.0; height: 380.0; page: 16;}; "><docset:Comments structure="p">

               Standardized liquid <dgm:_testRef>test </dgm:_testRef>meal will be administered at approximately <docset:TestMealAdministrationTime>08:00 </docset:TestMealAdministrationTime>(with allowance to <docset:MealConsumptionTime>11:00</docset:MealConsumptionTime>) and should be consumed within <docset:TestMealConsumptionTime>15 minutes </docset:TestMealConsumptionTime>(see Section <docset:TestMealAdministration>9.2.3.2</docset:TestMealAdministration>). <dgm:_testRef>Study </dgm:_testRef>periods to be separated by a minimum <docset:WashoutPeriod>21-hour </docset:WashoutPeriod>washout. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 631.0; width: 2738.0; height: 487.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 630.0; width: 456.0; height: 488.0; page: 17;}; ">

               <dgm:_testRef>Study </dgm:_testRef>drug administration </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 630.0; width: 258.0; height: 488.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 630.0; width: 224.0; height: 488.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 630.0; width: 282.0; height: 488.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 630.0; width: 236.0; height: 488.0; page: 17;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 630.0; width: 356.0; height: 488.0; page: 17;}; "><docset:StudyDrugAdministrationFollow-UpEarlyDiscontinuation>

                      X </docset:StudyDrugAdministrationFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 630.0; width: 320.0; height: 488.0; page: 17;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 630.0; width: 606.0; height: 488.0; page: 17;}; "><docset:Comments structure="p">

               Either immediately before meal or <docset:DosingSchedule>20 minutes </docset:DosingSchedule>after start of meal according to randomization schedule: <dgm:_testRef>Study </dgm:_testRef>drug will be administered at approximately the same time on Day <dgc:Number>1 </dgc:Number>of Periods <docset:StudyDrugAdministrationSchedule>1</docset:StudyDrugAdministrationSchedule>-<docset:StudyDrugAdministrationSchedule>4</docset:StudyDrugAdministrationSchedule>. There will be at least <docset:DoseInterval>21 hours </docset:DoseInterval>between <dgm:_testRef>study </dgm:_testRef>doses. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1119.0; width: 2738.0; height: 217.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1118.0; width: 456.0; height: 218.0; page: 17;}; "><dg:chunk structure="p">

               Injection site local tolerability assessments </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1118.0; width: 258.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1118.0; width: 224.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1118.0; width: 282.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1118.0; width: 236.0; height: 218.0; page: 17;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1118.0; width: 356.0; height: 218.0; page: 17;}; "><docset:InjectionSiteLocalTolerabilityAssessmentsFollow-UpEarlyDiscontinuation structure="h1">

                 <docset:PostdoseTime>0</docset:PostdoseTime>, <docset:PostdoseTime>20</docset:PostdoseTime>, and <docset:PostdoseTime>60 </docset:PostdoseTime>minutes postdose </docset:InjectionSiteLocalTolerabilityAssessmentsFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1118.0; width: 320.0; height: 218.0; page: 17;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1118.0; width: 606.0; height: 218.0; page: 17;}; "><docset:Comments structure="p">

               Assessments of injection site local tolerability will occur immediately following the injection. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1337.0; width: 2738.0; height: 378.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1336.0; width: 456.0; height: 379.0; page: 17;}; ">

               <dgm:Medication><dgm:Medication>Insulin </dgm:Medication>lispro </dgm:Medication>PK sampling </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1336.0; width: 258.0; height: 379.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1336.0; width: 224.0; height: 379.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1336.0; width: 282.0; height: 379.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1336.0; width: 236.0; height: 379.0; page: 17;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1336.0; width: 356.0; height: 379.0; page: 17;}; "><docset:InsulinLisproPKSamplingFollow-UpEarlyDiscontinuation structure="p">

               <docset:Predose>0 </docset:Predose>(predose), <docset:PostdoseTimePoints>5</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>10</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>15</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>20</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>25</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>30</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>35</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>40</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>45</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>50</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>55</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>60</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>70</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>90</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>120</docset:PostdoseTimePoints>, <docset:PostdoseTimepoints>150,180</docset:PostdoseTimepoints>, <docset:PostdoseTime>240</docset:PostdoseTime>, <docset:PostdoseTimePoints>300</docset:PostdoseTimePoints>, <docset:PostdoseTime>360</docset:PostdoseTime>, and <docset:PostdoseTime>420 </docset:PostdoseTime>minutes postdose </docset:InsulinLisproPKSamplingFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1336.0; width: 320.0; height: 379.0; page: 17;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1336.0; width: 606.0; height: 379.0; page: 17;}; "><docset:Comments structure="p">

               Sampling times are relative to the time of <dgm:_testRef>study </dgm:_testRef>drug administration in each period. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1716.0; width: 2738.0; height: 163.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1715.0; width: 456.0; height: 164.0; page: 17;}; ">

               Pharmacogenetics sample </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1715.0; width: 258.0; height: 164.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1715.0; width: 224.0; height: 164.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1715.0; width: 282.0; height: 164.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1715.0; width: 236.0; height: 164.0; page: 17;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1715.0; width: 356.0; height: 164.0; page: 17;}; "><docset:PharmacogeneticsSampleFollow-UpEarlyDiscontinuation structure="h1">

                  Predose for Period <docset:Predose>1 </docset:Predose>only </docset:PharmacogeneticsSampleFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1715.0; width: 320.0; height: 164.0; page: 17;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1715.0; width: 606.0; height: 164.0; page: 17;}; "><docset:Comments structure="h1">

               Refer to sample collection instructions provided by the sponsor. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1880.0; width: 2738.0; height: 271.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1879.0; width: 456.0; height: 272.0; page: 17;}; ">

               Immunogenicity sample </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 756.0; top: 1879.0; width: 258.0; height: 272.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1014.0; top: 1879.0; width: 224.0; height: 272.0; page: 17;}; "><docset:Screening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1238.0; top: 1879.0; width: 282.0; height: 272.0; page: 17;}; "><docset:Lead-in>

                Pre-<dgm:Medication>insulin </dgm:Medication>switch </docset:Lead-in></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1520.0; top: 1879.0; width: 236.0; height: 272.0; page: 17;}; "><docset:ImmunogenicitySampleStudyPeriodPeriods1to4 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1756.0; top: 1879.0; width: 356.0; height: 272.0; page: 17;}; "><docset:ImmunogenicitySampleFollow-UpEarlyDiscontinuation structure="h1">

                  Predose for Periods <docset:Predose>1 </docset:Predose>and <docset:PredosePeriods>3 </docset:PredosePeriods></docset:ImmunogenicitySampleFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2112.0; top: 1879.0; width: 320.0; height: 272.0; page: 17;}; "><docset:Follow-UpEarlyDiscontinuation>

                     X </docset:Follow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2432.0; top: 1879.0; width: 606.0; height: 272.0; page: 17;}; "><docset:Comments structure="p">

               Additional samples may be collected if the investigator considers there is a possibility that an AE is immunologically indicated. </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.9; top: 631.0; width: 2738.0; height: 217.0; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.9; top: 630.0; width: 456.0; height: 218.0; page: 18;}; ">

               C-peptide </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 755.9; top: 630.0; width: 258.0; height: 218.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1013.9; top: 630.0; width: 224.0; height: 218.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1237.9; top: 630.0; width: 282.0; height: 218.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1519.9; top: 630.0; width: 236.0; height: 218.0; page: 18;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1755.9; top: 630.0; width: 356.0; height: 218.0; page: 18;}; "><docset:C-peptideFollow-UpEarlyDiscontinuation structure="p">

                <docset:Predose>0 </docset:Predose>(predose), <docset:PostdoseTimePoints>30</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>60</docset:PostdoseTimePoints>, <docset:PostdoseTime>120</docset:PostdoseTime>, <docset:PostdoseTime>180</docset:PostdoseTime>, <docset:PostdoseTime>240</docset:PostdoseTime>, <docset:PostdoseTime>300</docset:PostdoseTime>, <docset:PostdoseTime>360 </docset:PostdoseTime>and <docset:PostdoseTime>420 </docset:PostdoseTime>minutes postdose </docset:C-peptideFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2111.9; top: 630.0; width: 320.0; height: 218.0; page: 18;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2431.9; top: 630.0; width: 606.0; height: 218.0; page: 18;}; "><docset:Comments structure="p">

               Sampling times are relative to the time of <dgm:_testRef>study </dgm:_testRef>drug administration </docset:Comments></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.9; top: 849.0; width: 2738.0; height: 163.0; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.9; top: 848.0; width: 456.0; height: 164.0; page: 18;}; ">

               Discharge from <docset:CRUDischarge>CRU </docset:CRUDischarge></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 755.9; top: 848.0; width: 258.0; height: 164.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1013.9; top: 848.0; width: 224.0; height: 164.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1237.9; top: 848.0; width: 282.0; height: 164.0; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1519.9; top: 848.0; width: 236.0; height: 164.0; page: 18;}; "><docset:Lead-in /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1755.9; top: 848.0; width: 356.0; height: 164.0; page: 18;}; "><docset:DischargeFromCRUFollow-UpEarlyDiscontinuation>

                      X </docset:DischargeFromCRUFollow-UpEarlyDiscontinuation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2111.9; top: 848.0; width: 320.0; height: 164.0; page: 18;}; "><docset:Follow-UpEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2431.9; top: 848.0; width: 606.0; height: 164.0; page: 18;}; "><docset:Comments structure="p">

               Patients may be discharged after all <dgm:_testRef>study </dgm:_testRef>procedures are completed. </docset:Comments></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:SignInformedConsentScreeningLead-inStudyPeriod></dg:chunk></dg:chunk><dg:chunk><docset:Abbreviations-section><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><docset:Abbreviations structure="div">CRU = clinical research unit; <dgm:MedicalTest>ECG </dgm:MedicalTest>= electrocardiogram; min = minutes; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; PK = pharmacokinetics. Note: The site should schedule activities as appropriate. In cases where several <dgm:_testRef>study </dgm:_testRef>procedures are scheduled at the same time, the order of priority will be as follows: PK samples including <dgm:MedicalTest>blood sampling </dgm:MedicalTest>for blood glucose and laboratory samples per protocol nominal times. ECGs and vital sign measurements should be scheduled before, but as close as possible to the PK sampling times. Injection-site assessments can be done after PK sampling. </docset:Abbreviations></docset:Abbreviations-section><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 1040; top: 291; width: 463; height: 72; page: 19;}; "><dg:chunk structure="li" style="boundingBox:{left: 1040; top: 291; width: 463; height: 72; page: 19;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1040; top: 291; width: 55; height: 72; page: 19;}; ">

                                                 3. </dg:chunk><dg:chunk>Introduction </dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:StudyObjectives structure="ol" style="list-style-type: decimal; boundingBox:{left: 291; top: 426; width: 1954; height: 1663; page: 19;}; "><dg:chunk structure="li" style="boundingBox:{left: 291; top: 426; width: 1954; height: 977.0; page: 19;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295; top: 426; width: 113; height: 67; page: 19;}; ">

              3.1. </dg:chunk><docset:StudyRationale-section><docset:StudyRationale structure="h1"><dgm:_testRef>Study </dgm:_testRef>Rationale </docset:StudyRationale><docset:StudyRationale structure="div">A prandial <dgm:Medication>insulin </dgm:Medication>with faster-on and/or faster-off characteristics might reduce glycemic excursions and the incidence of postprandial <dgm:Condition>hypoglycemia </dgm:Condition>compared to currently available fast-acting <dgm:Medication>insulin </dgm:Medication>analogs. LY900014 is an ultra-rapid-acting <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation that has shown an increased early absorption compared to commercially available <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>®; <docset:StudyDescription>Eli Lilly</docset:StudyDescription>). <dg:chunk>LY900014 </dg:chunk>aims to closely mimic the physiological prandial <dgm:Medication>insulin </dgm:Medication>secretion pattern, which may more effectively control postprandial glucose excursions and allow increased flexibility of the time of dosing relative to a meal.               This <dgm:_testRef>study </dgm:_testRef>aims to compare PK and PD profiles as well as the improved action of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>from LY900014 on the control of postprandial blood glucose in comparison to <dgm:Medication>Humalog </dgm:Medication>in patients with type 2 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>(T2DM). The improved action of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>will be assessed by using standardized mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>(MMTT). Furthermore, this <dgm:_testRef>study </dgm:_testRef>will explore the postprandial glucose profiles with LY900014 and <dgm:Medication>Humalog </dgm:Medication>injected at <docset:StudyDescription>2 </docset:StudyDescription>different meal-to-dose time intervals either immediately before or <docset:StudyDescription>20 minutes </docset:StudyDescription>following the start of the <dgm:_testRef>test </dgm:_testRef>meal to optimize future use of this investigational medicinal product (IMP). </docset:StudyRationale></docset:StudyRationale-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 292; top: 1459; width: 1951; height: 630; page: 19;}; "><dg:chunk structure="lim" style="boundingBox:{left: 294; top: 1459; width: 116; height: 65; page: 19;}; ">

              3.2. </dg:chunk><docset:Background-section><dg:chunk structure="h1">Background </dg:chunk><docset:Background structure="div">The <dgm:Medication>insulin </dgm:Medication>analog <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>) has been shown to be absorbed more quickly than regular human <dgm:Medication>insulin </dgm:Medication>(<dgm:Medication>Humalog </dgm:Medication>package insert, <docset:InsulinLisproAbsorption>2015</docset:InsulinLisproAbsorption>). In healthy volunteers given subcutaneous (SC) doses of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>ranging from <docset:InsulinAbsorptionProfile>0.1 </docset:InsulinAbsorptionProfile>to <docset:InsulinAbsorptionProfile>0.4 </docset:InsulinAbsorptionProfile>units/kg, peak serum levels were seen <docset:InsulinAbsorptionProfile>30 </docset:InsulinAbsorptionProfile>to <docset:InsulinLisproAbsorption>90 minutes </docset:InsulinLisproAbsorption>after dosing (<dgm:Medication>Humalog </dgm:Medication>package insert, <dg:chunk xsi:type="date">2015</dg:chunk>). However, the general consensus is that rapid-acting <dgm:Medication>insulin </dgm:Medication>is still not rapid enough to match carbohydrate absorption profiles, which limits efficacy and dosing flexibility. An ultra-rapid-acting prandial <dgm:Medication>insulin </dgm:Medication>would shift the PK/glucodynamics (GD) of <dgm:Medication>insulin </dgm:Medication>analogs so that they have an even faster onset to better match carbohydrate absorption and also allow greater flexibility in the time of dosing relative to meals. </docset:Background></docset:Background-section></dg:chunk></docset:StudyObjectives><dg:chunk><docset:NewFormulation structure="p">

              <docset:FormulationDescription>LY900014 </docset:FormulationDescription>represents a new formulation that contains <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, <dgm:Medication>treprostinil</dgm:Medication>, citrate, and other excipients. This formulation involves the novel use of a microdose of <dgm:Medication>treprostinil </dgm:Medication></docset:NewFormulation><docset:ExcipientComposition structure="p">

                            as an excipient to enhance the absorption of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>by local vasodilatation rather than as an active pharmaceutical ingredient to elicit a systemic effect. <dgm:Medication>Treprostinil </dgm:Medication>is a prostacyclin analogue, administered either through inhalation ), as an intravenous (IV) infusion or as a continuous SC administration for the treatment of symptomatic pulmonary arterial <dgm:Condition>hypertension </dgm:Condition>(PAH) and has been approved in the US since <docset:ExcipientDatabase>2002 </docset:ExcipientDatabase>and in Germany since 2006 (AMIS database [WWW]). <dgm:Medication>Sodium </dgm:Medication>citrate, an excipient that speeds <dgm:Medication>insulin </dgm:Medication>absorption (at least in part by enhancing vascular permeability), is also included in the formulation to further enhance the absorption of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>. Each of the other excipients (such as <dgm:Medication><dgm:Medication>magnesium </dgm:Medication>chloride</dgm:Medication>) in the LY900014 formulation is listed in the <docset:ExcipientSafety>US Food and Drug Administration 

              (FDA)</docset:ExcipientSafety>'s Generally Recognized as Safe Food Additives database and in the <docset:ExcipientSafety>FDA</docset:ExcipientSafety>'s Inactive Ingredients in Approved Drugs database. Furthermore, the excipient concentration in LY900014 is within the limits identified for approved drug products in the <dgc:Org>FDA</dgc:Org>'s Inactive Ingredients in Approved Drugs database. </docset:ExcipientComposition></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:LY900014StudyResults structure="p">

              To date, LY900014 has been administered to approximately <docset:PatientExposure>89 </docset:PatientExposure>patients with <dgm:Condition>diabetes </dgm:Condition>(<docset:AdverseEvents>60 </docset:AdverseEvents><dg:chunk>T1DM </dg:chunk>and 29 T2DM) across <docset:AdverseEvents>3 </docset:AdverseEvents>Phase 1b studies and approximately <docset:NumberofHealthyVolunteers>107 </docset:NumberofHealthyVolunteers>healthy volunteers across these Phase 1 studies. The total <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>exposure was similar between <docset:SafetyProfile>LY900014 </docset:SafetyProfile>and <dgm:Medication>Humalog</dgm:Medication>; however LY900014 demonstrated a faster and earlier <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>absorption compared to <dgm:Medication>Humalog</dgm:Medication>. Additionally, through the use of multiple <dgc:Frequency>daily </dgc:Frequency>injections of <dg:chunk>LY900014 </dg:chunk>in patients for up to <docset:TreatmentDuration>2 weeks </docset:TreatmentDuration>with either <dg:chunk>T1DM </dg:chunk>or T2DM, it was found that LY900014 was well tolerated. There were no serious adverse events (SAEs) related to <dgm:_testRef>study </dgm:_testRef>treatment or discontinuations from the studies because of a drug-related AE. Small numbers of treatment-emergent adverse events (TEAEs) were reported, and there were no notable increases in these events in relation to any of the <dg:chunk>LY900014 </dg:chunk>formulations compared to those in relation to <dgm:Medication>Humalog</dgm:Medication>. There were no reported cases of severe <dgm:Condition>hypoglycemia</dgm:Condition>. Additionally, there were no reported incidences of local or systemic allergic reactions. </docset:LY900014StudyResults><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 293; top: 1262; width: 856; height: 59.4; page: 20;}; "><docset:StudyRisksandBenefits structure="li" style="boundingBox:{left: 289; top: 1262; width: 1951; height: 1282; page: 20;}; "><dg:chunk structure="lim" style="boundingBox:{left: 293; top: 1262; width: 112; height: 60; page: 20;}; ">

              3.3. </dg:chunk><docset:BenefitRiskAssessment-section><dg:chunk structure="h1">Benefit/Risk Assessment </dg:chunk><docset:BenefitRiskAssessment structure="div">              This <dgm:_testRef>study </dgm:_testRef>will not offer any direct benefits to the patients participating in the <dgm:_testRef>study</dgm:_testRef>. The data from previous studies in healthy subjects and patients with <dg:chunk>T1DM </dg:chunk>and T2DM have shown that LY900014 was well tolerated and the adverse drug reactions are in keeping with those reported for <dgm:Medication>Humalog</dgm:Medication>.               Potential risks associated with LY900014, derived from the known risks of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>), are <dgm:Condition>hypoglycemia</dgm:Condition>, hypersensitivity reactions (localized <dgm:Condition>allergy </dgm:Condition>and/or systemic <dgm:Condition>allergy</dgm:Condition>), undesirable effects at the injection site (injection-site reactions and <dgm:Condition>lipodystrophy</dgm:Condition>), and peripheral <dgm:Condition>edema </dgm:Condition>(<dgm:Medication>Humalog </dgm:Medication>package insert, <docset:RisksandBenefits>2015</docset:RisksandBenefits>).               Notably, across all doses in the studies that have evaluated <dgm:Medication>treprostinil </dgm:Medication>as a local vasodilator with or without <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, there was no clinically significant increase in those AEs associated with systemic absorption of <dgm:Medication>treprostinil</dgm:Medication>, as described in the package insert (<docset:TreprostinilExposure>2014</docset:TreprostinilExposure>). The exposures of <dgm:Medication>treprostinil </dgm:Medication>in LY900014 in this <dgm:_testRef>study </dgm:_testRef>are expected to be undetectable compared to those observed in the dose ranges previously explored with SC bolus administration of <dgm:Medication>treprostinil </dgm:Medication>and are expected to be substantially lower than those observed in the treatment of PAH. No known potential risks are associated with the use of small amounts of <dgm:Medication>treprostinil </dgm:Medication>in the LY900014 formulation.               In preclinical safety pharmacology and toxicity studies, or clinical pharmacology studies involving <dg:chunk>LY900014 </dg:chunk>or <dgm:Medication>treprostinil </dgm:Medication>alone, other than known risks associated with <dgm:Medication>Humalog </dgm:Medication>and </docset:BenefitRiskAssessment></docset:BenefitRiskAssessment-section></docset:StudyRisksandBenefits></dg:chunk><dg:chunk><docset:StudyProcedures structure="p">

                        , no additional risks were identified. Additionally, local and systemic toxicity profiles of <dgm:Medication>Humalog </dgm:Medication>and do not suggest the potential for additive or synergistic toxicity. The <dgm:_testRef>study </dgm:_testRef>includes inpatient procedures during which participants will be continuously monitored. Patients will be without food intake from the start of the MMTT to completion of blood collection (approximately <docset:StudyDuration>420 minutes</docset:StudyDuration>) unless required to treat <dgm:Condition>hypoglycemia</dgm:Condition>, (see Section 

              <docset:HypoglycemiaDefinition>9.5.6.2 </docset:HypoglycemiaDefinition>for definition of <dgm:Condition>hypoglycemia </dgm:Condition>and Section <docset:TreatmentGuidelines>9.5.8 </docset:TreatmentGuidelines>for treatment guidelines). If a patient </docset:StudyProcedures><docset:InsulinAdministration structure="p">

              experiences elevated blood glucose following food intake for more than <docset:BloodGlucoseMonitoring>1 hour</docset:BloodGlucoseMonitoring>, <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glulisine </dgm:Medication>will be administered intravenously (see Section 9.5.8 for treatment guidelines). Patients will maintain their basal <dgm:Medication>insulin </dgm:Medication>regimen of site-provided <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine </dgm:Medication>during the entire <dgm:_testRef>study </dgm:_testRef>including the <docset:MMTTDays>MMTT days </docset:MMTTDays>unless safety issues arise; in this case, the investigator will discuss a change of the basal <dgm:Medication>insulin </dgm:Medication>regimen with the sponsor clinical pharmacologist (CP) and implement this change, if necessary, to prevent any medical problems. </docset:InsulinAdministration></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:InvestigatorsBrochure structure="p">

              More information about the known and expected benefits, risks, SAEs, and reasonably anticipated AEs of <docset:InvestigatorsBrochure>LY900014 </docset:InvestigatorsBrochure>are to be found in the Investigator’s Brochure (IB). </docset:InvestigatorsBrochure><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 825.0; top: 308.3; width: 895.8; height: 66.7; page: 22;}; "><dg:chunk structure="li" style="boundingBox:{left: 825.0; top: 308.3; width: 895.8; height: 66.7; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 825.0; top: 308.3; width: 58.3; height: 66.7; page: 22;}; ">

                                       4. </dg:chunk><dg:chunk>Objectives and Endpoints </dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk></docset:Glucodynamic></docset:Glucodynamic-section><dg:chunk structure="h1">

              Table <docset:StudyObjectivesandEndpoints>ITRW.1 </docset:StudyObjectivesandEndpoints>shows the objectives and endpoints of the <dgm:_testRef>study</dgm:_testRef>. </dg:chunk><dg:chunk><dg:chunk structure="h1">

              Table <docset:ITRW>ITRW.1</docset:ITRW>. </dg:chunk><docset:ObjectivesAndEndpoints-section structure="div"><dg:chunk structure="h1">

                                     Objectives and Endpoints </dg:chunk><docset:ObjectivesAndEndpoints structure="div"><dg:chunk><docset:ObjectivesAndEndpoints><xhtml:table structure="table" style="boundingBox:{left: 277.0; top: 609.8; width: 1948.0; height: 1324.0; page: 22;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 277.0; top: 609.8; width: 1948.0; height: 1324.0; page: 22;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 277.0; top: 609.8; width: 1948.0; height: 98.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 277.0; top: 609.8; width: 974.0; height: 98.0; page: 22;}; "><dg:chunk structure="h1">

                               Objectives </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1251.0; top: 609.8; width: 974.0; height: 98.0; page: 22;}; "><docset:Objectives structure="h1">

                               Endpoints </docset:Objectives></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 277.0; top: 708.8; width: 1948.0; height: 315.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 277.0; top: 707.8; width: 974.0; height: 316.0; page: 22;}; "><docset:Primary-section><dg:chunk structure="h1">

              Primary </dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 825.0; width: 904.2; height: 166.7; page: 22;}; "><docset:Primary structure="li" style="boundingBox:{left: 300.0; top: 825.0; width: 904.2; height: 166.7; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 825.0; width: 29.2; height: 41.7; page: 22;}; ">

              1. </dg:chunk><dg:chunk>To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC injection of <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>in patients with T2DM. </dg:chunk></docset:Primary></dg:chunk></docset:Primary-section></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1251.0; top: 707.8; width: 974.0; height: 316.0; page: 22;}; "><docset:Endpoints structure="h1">

              <docset:EarlyAUC>1</docset:EarlyAUC>. Early <docset:EarlyTmax>50% </docset:EarlyTmax>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </docset:Endpoints></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 277.0; top: 1024.8; width: 1948.0; height: 537.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 277.0; top: 1023.8; width: 974.0; height: 538.0; page: 22;}; "><docset:Objectives><dg:chunk structure="h1">

              Secondary </dg:chunk><docset:StudyObjectives structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 1141.7; width: 916.7; height: 387.5; page: 22;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1141.7; width: 916.7; height: 291.7; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1141.7; width: 29.2; height: 41.7; page: 22;}; ">

              1. </dg:chunk><docset:StudyDesign structure="p">To evaluate the effect of injection-to-meal timings (immediately before the start of meal, and <docset:Injection-to-MealTiming>20 minutes </docset:Injection-to-MealTiming>following the start of the meal) on the GD response to <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog</dgm:Medication>, as measured by the <docset:MealToleranceTest>MMTT</docset:MealToleranceTest>. </docset:StudyDesign></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1488.4; width: 770.0; height: 40.8; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1487.5; width: 29.2; height: 41.7; page: 22;}; ">

              2. </dg:chunk><dg:chunk>To evaluate the tolerability of <docset:DrugName>LY900014</docset:DrugName>. </dg:chunk></dg:chunk></docset:StudyObjectives></docset:Objectives></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1251.0; top: 1023.8; width: 974.0; height: 538.0; page: 22;}; "><docset:Endpoints structure="ol" style="list-style-type: decimal; boundingBox:{left: 1275.0; top: 1141.7; width: 600.0; height: 387.5; page: 22;}; "><dg:chunk structure="li" style="boundingBox:{left: 1275.0; top: 1141.7; width: 570.8; height: 42.4; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1275.0; top: 1141.7; width: 29.2; height: 41.7; page: 22;}; ">

              1. </dg:chunk><dg:chunk><dgc:Number>∆AUC(0</dgc:Number>-<docset:_2-HourAUC>2hr</docset:_2-HourAUC>), <docset:AUCChange>∆AUC(0</docset:AUCChange>-<docset:AUCat5Hours>5hr</docset:AUCat5Hours>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 1275.0; top: 1487.5; width: 600.0; height: 41.7; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1275.0; top: 1487.5; width: 29.2; height: 41.7; page: 22;}; ">

              2. </dg:chunk><dg:chunk>AEs and hypoglycemic events </dg:chunk></dg:chunk></docset:Endpoints></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 277.0; top: 1562.8; width: 1948.0; height: 203.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 277.0; top: 1561.8; width: 974.0; height: 204.0; page: 22;}; "><docset:Exploratory-section><dg:chunk structure="h1">

              Exploratory </dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 301.4; top: 1641.7; width: 794.4; height: 104.2; page: 22;}; "><docset:Exploratory structure="li" style="boundingBox:{left: 301.4; top: 1641.7; width: 794.4; height: 104.2; page: 22;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1641.7; width: 29.2; height: 41.7; page: 22;}; ">

              1. </dg:chunk><dg:chunk>To assess C-peptide levels following administration of <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog</dgm:Medication>. </dg:chunk></docset:Exploratory></dg:chunk></docset:Exploratory-section></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1252.0; top: 1561.8; width: 973.0; height: 204.0; page: 22;}; "><docset:Endpoints>

              <docset:C-peptideConcentration>1</docset:C-peptideConcentration>. C-peptide concentration </docset:Endpoints></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 277.0; top: 1766.8; width: 1948.0; height: 167.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 277.0; top: 1765.8; width: 974.0; height: 168.0; page: 22;}; "><docset:Objectives structure="p">

              <docset:ExploreAnti-DrugAntibodies>2</docset:ExploreAnti-DrugAntibodies>. Explore the formation of anti-drug antibodies to <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>. </docset:Objectives></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1252.0; top: 1765.8; width: 973.0; height: 168.0; page: 22;}; "><docset:Endpoints>

              <docset:Anti-insulinlisproantibodies>2</docset:Anti-insulinlisproantibodies>. Anti-<dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>antibodies </docset:Endpoints></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ObjectivesAndEndpoints><docset:Abbreviations-section><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><docset:Abbreviations structure="div">AE = adverse event; <docset:AreaUndertheCurve>AUC(0</docset:AreaUndertheCurve>-<docset:MaximumTime>30min</docset:MaximumTime>) = area under the concentration versus time curve (AUC) from 

                time zero to <docset:TimeFrame>30 minutes</docset:TimeFrame>; ∆AUC = area under the baseline subtracted glucose concentration versus time curve; early <docset:Percentage>50% </docset:Percentage>tmax = time to early half-maximal drug concentration; GD = glucodynamics; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; PK = pharmacokinetics; SC = subcutaneous; T2DM = Type <docset:StudyDesign>2 </docset:StudyDesign><dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus</dgm:Condition>. </docset:Abbreviations></docset:Abbreviations-section></dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 1020.8; top: 308.3; width: 500.0; height: 66.7; page: 23;}; "><dg:chunk structure="li" style="boundingBox:{left: 1020.8; top: 308.3; width: 500.0; height: 66.7; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1020.8; top: 308.3; width: 58.3; height: 66.7; page: 23;}; ">

                                                5. </dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 441.7; width: 554.2; height: 54.0; page: 23;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 441.7; width: 554.2; height: 54.0; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 441.7; width: 95.8; height: 58.3; page: 23;}; ">

              5.1. </dg:chunk><dg:chunk>Overall Design </dg:chunk></dg:chunk></dg:chunk><docset:StudyDesign structure="p">

              <dg:chunk><dgm:_testRef>Study </dgm:_testRef>ITRW </dg:chunk>is a Phase 1, patient- and investigator-blind, randomized, 2-treatment, 4-period crossover <dgm:_testRef>study </dgm:_testRef>in patients with T2DM to evaluate the <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>PK and GD characteristics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>following a single SC injection administered at <docset:StudyDescription>2 </docset:StudyDescription>different injection-to-mealtime intervals; either immediately before or <docset:Injection-to-MealtimeInterval>20 minutes </docset:Injection-to-MealtimeInterval>following the start of the <dgm:_testRef>test </dgm:_testRef>meal. <dg:chunk><dgm:_testRef>Study </dgm:_testRef>ITRW </dg:chunk>may be conducted at <docset:StudyDescription>1 </docset:StudyDescription>or more clinical research units (CRUs). </docset:StudyDesign></dg:chunk><dg:chunk structure="ul" style="list-style-type: circle; boundingBox:{left: 517; top: 1746.3; width: 1451; height: 29.7; page: 23;}; "><dg:chunk structure="li" style="boundingBox:{left: 517; top: 1746.3; width: 1451; height: 29.7; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 517; top: 1748; width: 24; height: 22; page: 23;}; ">

                        • </dg:chunk><dg:chunk>Weeks Day <docset:WeeksDay-1>-1 </docset:WeeksDay-1>Day i = <docset:Weeks>6 </docset:Weeks><docset:Weeks>Weeks </docset:Weeks></dg:chunk></dg:chunk></dg:chunk><docset:StudyDesign><xhtml:table structure="table" style="boundingBox:{left: 334; top: 1808; width: 1880; height: 394; page: 23;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 334; top: 1808; width: 1880; height: 394; page: 23;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 334; top: 1808; width: 1880; height: 76; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 334; top: 1808; width: 18; height: 76; page: 23;}; " /><xhtml:td structure="td" style="boundingBox:{left: 352; top: 1808; width: 296; height: 76; page: 23;}; ">

                Treatment </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 648; top: 1808; width: 654; height: 76; page: 23;}; ">

                 <docset:InsulinType>LY900014 </docset:InsulinType>or <dgm:Medication>Humalog </dgm:Medication></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1302; top: 1808; width: 912; height: 76; page: 23;}; "><dg:chunk structure="h1">

                 <dg:chunk>Dose Timing Relative </dg:chunk>to Meal (minute)* </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 334; top: 1885; width: 1880; height: 83; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 334; top: 1884; width: 18; height: 84; page: 23;}; " /><xhtml:td structure="td" style="boundingBox:{left: 352; top: 1884; width: 296; height: 84; page: 23;}; "><docset:Treatment>

                A </docset:Treatment></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 648; top: 1884; width: 654; height: 84; page: 23;}; "><docset:Ly900014OrHumalog>

                 <docset:LY900014>LY900014 </docset:LY900014></docset:Ly900014OrHumalog></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1302; top: 1884; width: 912; height: 84; page: 23;}; "><docset:DoseTimingRelativetoMealMinute>

                 <dgc:Number>0 </dgc:Number></docset:DoseTimingRelativetoMealMinute></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 334; top: 1969; width: 1880; height: 85; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 334; top: 1968; width: 314; height: 86; page: 23;}; " colspan="2">

                  B </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 648; top: 1968; width: 654; height: 86; page: 23;}; "><docset:Ly900014OrHumalog>

                 <docset:LY900014>LY900014 </docset:LY900014></docset:Ly900014OrHumalog></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1302; top: 1968; width: 912; height: 86; page: 23;}; "><docset:DoseTimingRelativetoMealMinute>

                 <dgc:Number>+20 </dgc:Number></docset:DoseTimingRelativetoMealMinute></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 334; top: 2055; width: 1880; height: 71; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 334; top: 2054; width: 314; height: 72; page: 23;}; " colspan="2">

                 C </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 648; top: 2054; width: 654; height: 72; page: 23;}; "><docset:Ly900014OrHumalog>

                 <dgm:Medication>Humalog </dgm:Medication></docset:Ly900014OrHumalog></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1302; top: 2054; width: 912; height: 72; page: 23;}; "><docset:DoseTimingRelativetoMealMinute>

                 <dgc:Number>0 </dgc:Number></docset:DoseTimingRelativetoMealMinute></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 334; top: 2127; width: 1880; height: 75; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 334; top: 2126; width: 314; height: 76; page: 23;}; " colspan="2">

                  D </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 648; top: 2126; width: 654; height: 76; page: 23;}; "><docset:Ly900014OrHumalog>

                 <dgm:Medication>Humalog </dgm:Medication></docset:Ly900014OrHumalog></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1302; top: 2126; width: 912; height: 76; page: 23;}; "><docset:DoseTimingRelativetoMealMinute>

                 <dgc:Number>+20 </dgc:Number></docset:DoseTimingRelativetoMealMinute></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:StudyDesign><dg:chunk><dg:chunk structure="ul" style="list-style-type: circle; boundingBox:{left: 383; top: 2239; width: 620; height: 32; page: 23;}; "><dg:chunk structure="li" style="boundingBox:{left: 383; top: 2239; width: 620; height: 32; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 383; top: 2239; width: 12; height: 14; page: 23;}; ">

                  • </dg:chunk><dg:chunk><dg:chunk>Time O </dg:chunk>is immediately before <dgm:_testRef>test </dgm:_testRef>meal </dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="h1">

                                     Abbreviations: </dg:chunk><dg:chunk structure="div">ED = early discontinuation; <docset:Diagnosis>T2DM </docset:Diagnosis>= type <docset:EarlyDiscontinuationRate>2 </docset:EarlyDiscontinuationRate><dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition></dg:chunk></dg:chunk></dg:chunk></docset:ObjectivesAndEndpoints></docset:ObjectivesAndEndpoints-section></dg:chunk><docset:FigureITRW1-section><dg:chunk structure="h1">

              Figure ITRW.1. </dg:chunk><docset:FigureITRW1 structure="div"><docset:IllustrationofStudyDesignforProtocolI8B-MC-ITRW-section><dg:chunk structure="h1">

                                     Illustration of <dgm:_testRef>study </dgm:_testRef>design for Protocol I8B-MC-ITRW. </dg:chunk><docset:IllustrationofStudyDesignforProtocolI8B-MC-ITRW structure="div"><dg:chunk><docset:PatientAttendanceRequirements structure="p">

              Patients will be required to attend the CRU on at least <docset:NumberofVisits>8 </docset:NumberofVisits>occasions (no more than <docset:MaximumNumberofVisits>10 </docset:MaximumNumberofVisits>occasions if dose-finding and/or one MMTT rescheduled) as noted in the <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Schedule </dg:chunk>(see Section 2): </docset:PatientAttendanceRequirements><docset:StudyVisits structure="ul" style="list-style-type: circle; boundingBox:{left: 375.0; top: 2679.2; width: 1187.5; height: 240.8; page: 23;}; boundingBox:{left: 372.6; top: 304; width: 1611.4; height: 200; page: 24;}; "><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 2679.2; width: 420.8; height: 53.9; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 2679.2; width: 20.8; height: 50.0; page: 23;}; ">

                  • </dg:chunk><dg:chunk>Informed consent </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 2770.8; width: 370.8; height: 58.3; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 2770.8; width: 20.8; height: 58.3; page: 23;}; ">

                  • </dg:chunk><dg:chunk><dgm:_testRef>Screening </dgm:_testRef>visit </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 2866.7; width: 1187.5; height: 53.3; page: 23;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 2866.7; width: 20.8; height: 54.2; page: 23;}; ">

                  • </dg:chunk><dg:chunk>Lead-in and <dgm:Medication>insulin </dgm:Medication>transition period (see Section <docset:Lead-inandInsulinTransitionPeriod>9.2.1</docset:Lead-inandInsulinTransitionPeriod>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 441; top: 304; width: 1543; height: 111; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 372; top: 314; width: 23; height: 38; page: 24;}; ">

                 • </dg:chunk><dg:chunk><docset:NumberofStudyVisits>4 </docset:NumberofStudyVisits>inpatient CRU <dgm:_testRef>study </dgm:_testRef>visits (including dose finding assessment [see Section <docset:InpatientStudyVisits>9.2.2</docset:InpatientStudyVisits>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 377; top: 455.4; width: 427.0; height: 48.6; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 377; top: 471; width: 19; height: 19; page: 24;}; ">

                  • </dg:chunk><dg:chunk>A follow-up visit. </dg:chunk></dg:chunk></docset:StudyVisits></dg:chunk><docset:InsulinTransitionPeriod structure="p">

              Eligible patients who have satisfied the entry criteria and completed all <dgm:_testRef>screening </dgm:_testRef>procedures will return to the <docset:Lead-InPeriod>CRU </docset:Lead-InPeriod>at least <docset:Lead-inPeriod>2 weeks </docset:Lead-inPeriod>prior to Period <docset:InsulinTransitionPeriod>1 </docset:InsulinTransitionPeriod>Day <docset:Lead-InPeriodStartDate>-2 </docset:Lead-InPeriodStartDate>to begin a lead-in and <dgm:Medication>insulin </dgm:Medication>transition period. When patients visit the CRU to begin the lead-in period, patients will receive instruction on general <dgm:Condition>diabetes </dgm:Condition>education including measurement of self-monitored plasma glucose (SMPG) and receive instruction on the <dgm:Medication>insulin </dgm:Medication>transition (see Section 9.2.1). During the <dgm:Medication>insulin </dgm:Medication>transition period, patients will transition from their current basal <dgm:Medication>insulin </dgm:Medication>therapy to </docset:InsulinTransitionPeriod></docset:IllustrationofStudyDesignforProtocolI8B-MC-ITRW></docset:IllustrationofStudyDesignforProtocolI8B-MC-ITRW-section><docset:FollowingInsulin-section><dg:chunk structure="h1">

                                                                              Following <dgm:Medication>insulin </dgm:Medication></dg:chunk><docset:FollowingInsulin structure="div"><docset:StudyDesign structure="p">transition, patients will return to the CRU for the dose-finding assessment (see Section 9.2.2) either on the evening of Day <docset:Dose-FindingAssessment>-2 </docset:Dose-FindingAssessment>or the morning of Day -1 Period 1. The dose-finding assessment will use <dgm:Medication>Humalog </dgm:Medication>administered immediately before a standardized liquid <dgm:_testRef>test </dgm:_testRef>meal (<docset:MealToleranceTest>MMTT</docset:MealToleranceTest>) to inform the dose of LY900014 and <dgm:Medication>Humalog </dgm:Medication>to be used during subsequent <dgm:_testRef>study </dgm:_testRef>MMTT assessments. Upon completion of the dose-finding assessment, patients will be randomised to <docset:Dose-FindingAssessment>1 </docset:Dose-FindingAssessment>of <docset:StudyPeriods>4 </docset:StudyPeriods>treatment sequences. Prior to the MMTT in each <dgm:_testRef>study </dgm:_testRef>period, patients will undergo a run-in period (see Section 9.2.3.1) to achieve a predetermined glucose target of <docset:GlucoseTarget>135 </docset:GlucoseTarget>+ 15 mg/dL (7.5+0.8 mmol/L). Once the glucose target has been attained, patients will proceed with the MMTT in which a single individualized SC dose of LY900014 or <dgm:Medication>Humalog </dgm:Medication>will be administered either immediately before the <dgm:_testRef>test </dgm:_testRef>meal or <docset:DoseAdministrationTime>20 minutes </docset:DoseAdministrationTime>following the start of the <dgm:_testRef>test </dgm:_testRef>meal (see Section </docset:StudyDesign><dg:chunk><dg:chunk structure="p">

              <dgc:Number>9.2.3.2</dgc:Number>). </dg:chunk><dg:chunk><docset:InsulinUse structure="p">

              Doses of <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>during the <docset:StudyPeriods>4 </docset:StudyPeriods><dgm:_testRef>study </dgm:_testRef>periods will be separated by a minimum washout of approximately <docset:MinimumWashoutPeriod>21 hours</docset:MinimumWashoutPeriod>. The maximum duration allowed for all <dgc:Number>4 </dgc:Number>periods is approximately <docset:MaximumDuration>6 weeks</docset:MaximumDuration>. Patients will continue using site-provided <dgm:Medication>Humalog </dgm:Medication>and <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine </dgm:Medication>during the washout periods between MMTTs (see Section 7.7 for use of concomitant medication and basal <dgm:Medication>insulin</dgm:Medication>). During the washout periods, patients will be instructed to perform regular blood glucose monitoring (see Section 9.5.6.4.). </docset:InsulinUse><docset:StudyProcedures structure="p">

              Following completion of all <dgm:_testRef>study </dgm:_testRef>procedures in each period, patients may be offered a meal and discharged from the CRU at the discretion of the principal investigator. </docset:StudyProcedures><dg:chunk><dg:chunk structure="p">

              <dgm:_testRef>Study </dgm:_testRef>governance considerations are described in detail in Appendix 3. </dg:chunk><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 300; top: 2372.9; width: 789; height: 59.0; page: 24;}; boundingBox:{left: 300.0; top: 325.0; width: 1166.7; height: 2116.7; page: 25;}; "><dg:chunk structure="li" style="boundingBox:{left: 296.0; top: 2372.9; width: 1944.8; height: 373.8; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300; top: 2367; width: 109; height: 65; page: 24;}; ">

              5.2. </dg:chunk><docset:NumberofParticipants-section><dg:chunk structure="h1">Number of Participants </dg:chunk><docset:NumberofParticipants structure="div">              Up to <docset:MaximumNumberofPatients>36 </docset:MaximumNumberofPatients>patients may be enrolled so that approximately <docset:MaximumNumberofPatients>30 </docset:MaximumNumberofPatients>patients complete the <dgm:_testRef>study</dgm:_testRef>. For purposes of this <dgm:_testRef>study</dgm:_testRef>, a patient completes the <dgm:_testRef>study </dgm:_testRef>when all scheduled procedures shown in the Schedule of Activities have been finished. Patients who drop out may be replaced, the replacement patient will adopt all <docset:NumberofPatients>4 </docset:NumberofPatients>assigned crossover treatments of the original patient's randomization schedule. </docset:NumberofParticipants></docset:NumberofParticipants-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 325.0; width: 1929.2; height: 179.2; page: 25;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 325.0; width: 95.8; height: 58.3; page: 25;}; ">

              5.3. </dg:chunk><docset:EndofStudyDefinition-section><dg:chunk structure="h1">End of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Definition </dg:chunk></dg:chunk><docset:EndofStudyDefinition structure="div">              End of the <dgm:_testRef>study </dgm:_testRef>is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient. </docset:EndofStudyDefinition></docset:EndofStudyDefinition-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 575.0; width: 1933.3; height: 1737.6; page: 25;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 575.0; width: 95.8; height: 58.3; page: 25;}; ">

              5.4. </dg:chunk><docset:ScientificRationaleforStudyDesign-section><dg:chunk structure="h1"><dg:chunk>Scientific Rationale </dg:chunk>for <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk></dg:chunk><docset:ScientificRationaleforStudyDesign structure="div">              The <dgm:_testRef>study </dgm:_testRef>is a 4-period crossover design to reduce the variability of <dgm:Medication>insulin </dgm:Medication>PK and GD as each patient will act as his/her own control. The total number of patients needed with a crossover design is less than the number needed with a parallel group design. A maximum duration of approximately <docset:StudyDuration>6 weeks </docset:StudyDuration>is allowed for patients to complete all <docset:StudyDesign>4 </docset:StudyDesign>assigned periods to minimize the risk of <dgm:Medication>insulin </dgm:Medication>resistance/changes in mean glycemic control during the <dgm:_testRef>study</dgm:_testRef>.               Randomization and blinding are used to avoid bias introduced through an association between allocation order of IMP and patient characteristics. The <docset:StudyDesign>Lilly CP</docset:StudyDesign>/<docset:StudyDesign>Lilly </docset:StudyDesign><dgm:_testRef>study </dgm:_testRef>team will be unblinded.               In each <dgm:_testRef>study </dgm:_testRef>period, patients will undergo a run-in period before the MMTT using a variable <dgm:Medication>insulin </dgm:Medication>and glucose intravenous (IV) infusion. This run-in period will allow for improved comparability of the postprandial glucose response to a mixed meal after treatment with LY900014 and <dgm:Medication>Humalog </dgm:Medication>administered either immediately before the start of the meal, or <docset:Run-inPeriod>20 minutes </docset:Run-inPeriod>following the start of the <dgm:_testRef>test </dgm:_testRef>meal. This run-in aims to achieve similar preprandial glucose levels for all patients before the start of the <dgm:_testRef>test </dgm:_testRef>meal and thereby reduces the variability of the postprandial glucose response. <dgm:Medication><dgm:Medication>Insulin </dgm:Medication>glulisine </dgm:Medication>has been chosen for the IV optimization of blood glucose during the run-in because <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glulisine </dgm:Medication>does not cross-react with the <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>–specific assay used for the PK analysis.               Under this design, if <docset:StudyDesign>2 </docset:StudyDesign>periods occur on consecutive days, the interval between the last bolus on the first day and the first bolus on the second day is much longer compared to the length of time that the treatment (<dg:chunk>LY900014 </dg:chunk>or <dgm:Medication>Humalog</dgm:Medication>) lasts in the bloodstream; therefore, no carryover effect is assumed. This enables PK and GD data from the breakfast meal tests of each period to be analyzed independently and separately.               A minimum of approximately <docset:StudyDesign>21 </docset:StudyDesign>hours washout between the <dgm:_testRef>test </dgm:_testRef>meals allows for a complete washout of <dgm:_testRef>study </dgm:_testRef>drug administered with the MMTT and glucose response and prevents carry- over effects. </docset:ScientificRationaleforStudyDesign></docset:ScientificRationaleforStudyDesign-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 2383.3; width: 741.7; height: 58.3; page: 25;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 2383.3; width: 95.8; height: 58.3; page: 25;}; ">

              5.5. </dg:chunk><dg:chunk>Justification for Dose </dg:chunk></dg:chunk></docset:StudyDesign></dg:chunk><dg:chunk><docset:InsulinDosing structure="p">

              The bolus dose of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<docset:InsulinLisproDose>LY900014 </docset:InsulinLisproDose>or <dgm:Medication>Humalog</dgm:Medication>) will be individualized per patient to cover the carbohydrate content in this standardized liquid <dgm:_testRef>test </dgm:_testRef>meal. This dose of <dgm:Medication>insulin </dgm:Medication>is reflective of clinically relevant, individualized <dgm:Medication>insulin </dgm:Medication>dosing, similar to how patients would determine the <dgm:Medication>insulin </dgm:Medication>dose for the carbohydrate content in a meal. For each patient, the individualized prandial <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>dose in LY900014 and <dgm:Medication>Humalog </dgm:Medication>for each <dgm:_testRef>test </dgm:_testRef>meal must be kept identical throughout the crossover periods. </docset:InsulinDosing><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 962.5; top: 308.3; width: 620.8; height: 66.7; page: 26;}; "><dg:chunk structure="li" style="boundingBox:{left: 962.5; top: 308.3; width: 620.8; height: 66.7; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 962.5; top: 308.3; width: 54.2; height: 66.7; page: 26;}; ">

                                             6. </dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Population </dg:chunk></dg:chunk></dg:chunk></dg:chunk><docset:PatientEligibilityCriteria structure="p">

              Eligibility of patients for <dgm:_testRef>study </dgm:_testRef>enrollment will be based on the results of <dgm:_testRef>screening </dgm:_testRef>medical history, physical <dgm:_testRef>examination</dgm:_testRef>, <dgm:MedicalTest>vital signs</dgm:MedicalTest>, clinical laboratory tests, and electrocardiogram (<dgm:MedicalTest>ECG</dgm:MedicalTest>). </docset:PatientEligibilityCriteria><docset:PhysicalExaminationFindings structure="p">

              The nature of any conditions present at the time of the physical <dgm:_testRef>examination </dgm:_testRef>and any preexisting conditions will be documented. </docset:PhysicalExaminationFindings><docset:ScreeningPeriod structure="p">

              <dgm:_testRef>Screening </dgm:_testRef>may occur over a <docset:ScreeningPeriod>14-day </docset:ScreeningPeriod>period prior to the lead-in site visit. Patients who are not entered within this time period, may be subjected to an additional medical assessment and/or clinical measurements to confirm their eligibility. </docset:ScreeningPeriod><dg:chunk><docset:RecruitmentandEnrollmentCriteria structure="p">

              Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted. </docset:RecruitmentandEnrollmentCriteria><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 1137.5; width: 625.0; height: 58.3; page: 26;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1137.5; width: 625.0; height: 58.3; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1137.5; width: 95.8; height: 58.3; page: 26;}; ">

              6.1. </dg:chunk><dg:chunk>Inclusion <docset:InclusionCriteria>Criteria </docset:InclusionCriteria></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:InclusionCriteria structure="p">

              Patients are eligible for inclusion in the <dgm:_testRef>study </dgm:_testRef>only if they meet all of the following criteria at <dgm:_testRef>screening </dgm:_testRef>and/or enrollment: </docset:InclusionCriteria><dg:chunk><docset:ContraceptionRequirements structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 450.0; top: 1358.3; width: 1595.8; height: 108.3; page: 26;}; boundingBox:{left: 445.8; top: 1358.3; width: 1640.2; height: 1491.7; page: 27;}; "><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1358.3; width: 1595.8; height: 433.3; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1358.3; width: 58.3; height: 50.0; page: 26;}; ">

                     [1] </dg:chunk><dg:chunk><docset:PatientSelectionCriteria structure="p">are male or female patients with T2DM for at least <docset:DiagnosisDuration>1 year</docset:DiagnosisDuration>. A diagnosis of T2DM is based on medical history. </docset:PatientSelectionCriteria><docset:ContraceptionRequirements structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 600.0; top: 1504.2; width: 400.0; height: 287.5; page: 26;}; "><dg:chunk structure="li" style="boundingBox:{left: 600.0; top: 1504.2; width: 1358.3; height: 199.2; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 600.0; top: 1504.2; width: 33.3; height: 50.0; page: 26;}; ">

                            a. </dg:chunk><docset:MalePatients-section><dg:chunk structure="h1">Male patients: </dg:chunk><dg:chunk structure="ol" style="list-style-type: lower-roman; boundingBox:{left: 720.8; top: 1595.8; width: 1237.5; height: 107.5; page: 26;}; "><docset:MalePatients structure="li" style="boundingBox:{left: 720.8; top: 1595.8; width: 1237.5; height: 107.5; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 720.8; top: 1595.8; width: 25.0; height: 50.0; page: 26;}; ">

                                  i. </dg:chunk><dg:chunk>No male contraception required except in compliance with specific local government requirements. </dg:chunk></docset:MalePatients></dg:chunk></docset:MalePatients-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 600.0; top: 1741.7; width: 1491.7; height: 573.4; page: 26;}; boundingBox:{left: 695.8; top: 512.5; width: 1395.8; height: 105.4; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 600.0; top: 1741.7; width: 33.3; height: 50.0; page: 26;}; ">

                            b. </dg:chunk><docset:FemalePatients-section><dg:chunk structure="h1">Female patients: </dg:chunk><docset:FemalePatients structure="ol" style="list-style-type: lower-roman; boundingBox:{left: 708.3; top: 1829.2; width: 1383.3; height: 485.9; page: 26;}; boundingBox:{left: 695.8; top: 512.5; width: 1395.8; height: 105.4; page: 27;}; "><dg:chunk structure="li" style="boundingBox:{left: 720.8; top: 1829.2; width: 1370.8; height: 281.4; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 720.8; top: 1829.2; width: 25.0; height: 50.0; page: 26;}; ">

                                  i. </dg:chunk><docset:SexualActivityRequirements structure="p">Women of child-bearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same sex relationship without sexual relationships with males. </docset:SexualActivityRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 708.3; top: 2150.0; width: 1387.5; height: 808.3; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 708.3; top: 2150.0; width: 37.5; height: 50.0; page: 26;}; ">

                                 ii. </dg:chunk><dg:chunk><docset:PregnancyPrevention structure="p">Otherwise, women of child-bearing potential participating must agree to use <docset:ContraceptionAgreement>1 </docset:ContraceptionAgreement>highly effective method of contraception until discharge from final treatment period. </docset:PregnancyPrevention><docset:ContraceptionRequirements structure="ol" style="list-style-type: decimal; boundingBox:{left: 900.0; top: 2354.2; width: 1195.8; height: 604.2; page: 26;}; "><dg:chunk structure="li" style="boundingBox:{left: 900.0; top: 2354.2; width: 1191.7; height: 281.8; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 900.0; top: 2354.2; width: 37.5; height: 50.0; page: 26;}; ">

                                          1. </dg:chunk><dg:chunk>Women of child bearing potential must <dgm:_testRef>test </dgm:_testRef>negative for <dgm:Condition>pregnancy </dgm:Condition>prior to initiation of treatment as indicated by a negative serum <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>at the <dgm:_testRef>screening </dgm:_testRef>visit followed by a negative urine <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>within <docset:PregnancyTestingWindow>24 hours </docset:PregnancyTestingWindow>prior to exposure in Period 1. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 900.0; top: 2675.0; width: 1195.8; height: 283.3; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 900.0; top: 2675.0; width: 37.5; height: 50.0; page: 26;}; ">

                                          2. </dg:chunk><dg:chunk>A highly effective method of contraception includes a combined (estrogen and progestogen containing) or progestogen-only hormonal contraception administered orally, intravaginally, or transdermally and is associated with inhibition of ovulation. Alternatively, patients may use either an intrauterine device, intrauterine hormone-releasing system, bilateral tubal <dgm:Condition>occlusion</dgm:Condition>, or the partner should have been vasectomised. </dg:chunk></dg:chunk></docset:ContraceptionRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 695.8; top: 512.5; width: 1400.0; height: 808.3; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 695.8; top: 512.5; width: 50.0; height: 50.0; page: 27;}; ">

                                 iii. </dg:chunk><dg:chunk><dg:chunk structure="p">Women not of childbearing potential may participate and include those who are: </dg:chunk><docset:MenopausalStatusRequirements structure="ol" style="list-style-type: decimal; boundingBox:{left: 900.0; top: 658.3; width: 1195.8; height: 662.5; page: 27;}; "><dg:chunk structure="li" style="boundingBox:{left: 900.0; top: 658.3; width: 1100.0; height: 166.7; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 900.0; top: 658.3; width: 37.5; height: 50.0; page: 27;}; ">

                                          1. </dg:chunk><docset:InfertilityCause structure="p">infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or bilateral salpingectomy), congenital anomaly such as Mullerian <dgm:Condition>agenesis</dgm:Condition>; or </docset:InfertilityCause></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 975.0; top: 862.5; width: 1120.8; height: 458.3; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 900.0; top: 862.5; width: 37.5; height: 50.0; page: 27;}; ">

                                          2. </dg:chunk><dg:chunk>post-menopausal – defined as a woman being amenorrheic for more than <docset:Post-MenopausalDefinition>1 year </docset:Post-MenopausalDefinition>without an alternative medical cause and a serum follicle-stimulating hormone (FSH) level compatible with postmenopausal status. A FSH level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. </dg:chunk></dg:chunk></docset:MenopausalStatusRequirements></dg:chunk></dg:chunk></docset:FemalePatients></docset:FemalePatients-section></dg:chunk></docset:ContraceptionRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1358.3; width: 1304.2; height: 108.3; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1358.3; width: 58.3; height: 50.0; page: 27;}; ">

                     [2] </dg:chunk><dg:chunk>are aged <docset:AgeRange>18 </docset:AgeRange>to <docset:MaximumAge>70 years </docset:MaximumAge>inclusive at the time of <dgm:_testRef>screening</dgm:_testRef>.                                                                     <dgc:Number>2 </dgc:Number><docset:AgeRange>2 </docset:AgeRange></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1454.2; width: 1625.0; height: 108.3; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1454.2; width: 58.3; height: 50.0; page: 27;}; ">

                     [3] </dg:chunk><dg:chunk>have a body mass index (BMI) of <docset:MinimumBMI><docset:BMILowerLimit>18.5 </docset:BMILowerLimit>kg</docset:MinimumBMI>/m to <docset:MaximumBMI><docset:MaximumBMI>40.0 </docset:MaximumBMI>kg</docset:MaximumBMI>/m , both inclusive, at <dgm:_testRef>screening</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1600.0; width: 1575.0; height: 166.7; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1600.0; width: 58.3; height: 50.0; page: 27;}; ">

                     [4] </dg:chunk><dg:chunk>have clinical laboratory <dgm:_testRef>test </dgm:_testRef>results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1804.2; width: 1504.2; height: 108.3; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1804.2; width: 58.3; height: 50.0; page: 27;}; ">

                     [5] </dg:chunk><dg:chunk>have venous access sufficient to allow for glucose infusion and <dgm:MedicalTest>blood sampling </dgm:MedicalTest>procedures as per protocol. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1954.2; width: 1633.3; height: 103.8; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1954.2; width: 58.3; height: 50.0; page: 27;}; ">

                     [6] </dg:chunk><dg:chunk>are reliable and willing to make themselves available for the duration of the <dgm:_testRef>study </dgm:_testRef>and are willing to follow <dgm:_testRef>study </dgm:_testRef>procedures. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 2100.0; width: 1625.0; height: 104.2; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2100.0; width: 62.5; height: 50.0; page: 27;}; ">

                     [7] </dg:chunk><dg:chunk>are able and willing to give signed informed consent approved by <docset:Consent>Lilly </docset:Consent>and the ethical review board (ERB) governing the site. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 446.0; top: 2245.8; width: 1274.8; height: 50.0; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2245.8; width: 62.5; height: 50.0; page: 27;}; ">

                     [8] </dg:chunk><dg:chunk structure="p">have a glycated hemoglobin (HbA1c) <docset:HbA1cLimit>≤9.0% </docset:HbA1cLimit>at <dgm:_testRef>screening</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 446.0; top: 2333.3; width: 1587.3; height: 164.9; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2333.3; width: 62.5; height: 50.0; page: 27;}; ">

                     [9] </dg:chunk><dg:chunk>have a fasting C-peptide <docset:C-peptideLevel>≤1.0 </docset:C-peptideLevel>nmol/L. Patients who had C-peptide levels &gt;<docset:C-peptideLevel>1.0 </docset:C-peptideLevel>nmol/L may be retested once. If the retest yields a C-peptide <dgc:Number>≤1.0 </dgc:Number>nmol/L then the patient satisfies this criterion. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 2537.5; width: 1533.3; height: 105.5; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2537.5; width: 87.5; height: 50.0; page: 27;}; ">

                     [10] </dg:chunk><dg:chunk>have had no episodes of severe <dgm:Condition>hypoglycemia </dgm:Condition>in the last <docset:HypoglycemiaFreePeriod>6 months </docset:HypoglycemiaFreePeriod>(see Section <docset:NoSevereHypoglycemia>9.5.6.3</docset:NoSevereHypoglycemia>). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 2683.3; width: 1636.0; height: 166.7; page: 27;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 2683.3; width: 83.3; height: 50.0; page: 27;}; ">

                     [11] </dg:chunk><dg:chunk>are on stable prandial <dgm:Medication>insulin </dgm:Medication>and basal <dgm:Medication>insulin </dgm:Medication>(neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn [<dgm:Medication>NPH</dgm:Medication>] <dgm:Medication>insulin</dgm:Medication>, <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine </dgm:Medication>or <dgm:Medication><dgm:Medication>insulin </dgm:Medication>detemir</dgm:Medication>) with or without a stable dose of <dgm:Medication>metformin </dgm:Medication>for at least <docset:StableMedicationUse>3 months </docset:StableMedicationUse>before <dgm:_testRef>screening</dgm:_testRef>. </dg:chunk></dg:chunk></docset:ContraceptionRequirements><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 325.0; width: 641.7; height: 58.3; page: 28;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 325.0; width: 641.7; height: 58.3; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 325.0; width: 95.8; height: 58.3; page: 28;}; ">

              6.2. </dg:chunk><dg:chunk>Exclusion Criteria </dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:PatientExclusionCriteria structure="p">

              Patients will be excluded from <dgm:_testRef>study </dgm:_testRef>enrollment if they meet any of the following criteria at <dgm:_testRef>screening </dgm:_testRef>and/or enrollment: </docset:PatientExclusionCriteria><dg:chunk><docset:StudyExclusionCriteria structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 445.8; top: 545.8; width: 1645.8; height: 2383.3; page: 28;}; boundingBox:{left: 444; top: 302; width: 1655; height: 2633.8; page: 29;}; boundingBox:{left: 445.8; top: 308.3; width: 1633.3; height: 1129.2; page: 30;}; "><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 545.8; width: 1620.8; height: 166.7; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 545.8; width: 83.3; height: 50.0; page: 28;}; ">

                     [12] </dg:chunk><dg:chunk>are investigative site personnel directly affiliated with this <dgm:_testRef>study </dgm:_testRef>and their immediate families. Immediate family is defined as a spouse, biological or legal guardian, child, or sibling. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 750.0; width: 1441.7; height: 50.0; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 750.0; width: 83.3; height: 50.0; page: 28;}; ">

                     [13] </dg:chunk><dg:chunk>are Lilly employees or employees of the investigational site/CRU. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 837.5; width: 1483.3; height: 165.0; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 837.5; width: 83.3; height: 50.0; page: 28;}; ">

                     [14] </dg:chunk><dg:chunk>are currently enrolled in a clinical <dgm:_testRef>study </dgm:_testRef>involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this <dgm:_testRef>study</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1041.7; width: 1641.7; height: 166.0; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1041.7; width: 83.3; height: 50.0; page: 28;}; ">

                     [15] </dg:chunk><dg:chunk>have participated within the last <docset:ClinicalTrialParticipation>30 days </docset:ClinicalTrialParticipation>in a clinical trial involving an IP. If the previous IP has a long half-life, <docset:ClinicalTrialParticipation>3 months </docset:ClinicalTrialParticipation>or <docset:ClinicalTrialParticipation>5 </docset:ClinicalTrialParticipation>half-lives (whichever is longer) should have passed. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1245.8; width: 1262.5; height: 50.0; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1245.8; width: 83.3; height: 50.0; page: 28;}; ">

                     [16] </dg:chunk><dg:chunk>have previously completed or withdrawn from this <dgm:_testRef>study</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1333.3; width: 1582.0; height: 108.3; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1333.3; width: 83.3; height: 50.0; page: 28;}; ">

                     [17] </dg:chunk><dg:chunk>have an abnormality in the <docset:ECGAbnormality>12</docset:ECGAbnormality>-lead <dgm:MedicalTest>ECG </dgm:MedicalTest>that, in the opinion of the investigator, increases the risks associated with participating in the <dgm:_testRef>study</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 1479.2; width: 1625.0; height: 337.8; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1479.2; width: 87.5; height: 50.0; page: 28;}; ">

                     [18] </dg:chunk><dg:chunk>have a supine blood pressure at <dgm:_testRef>screening </dgm:_testRef>outside the range of <docset:BloodPressureRange>90 </docset:BloodPressureRange>to <docset:BloodPressureRange>160 </docset:BloodPressureRange>mmHg for systolic or <docset:BloodPressureRange>50 </docset:BloodPressureRange>to <docset:BloodPressureRange>100 </docset:BloodPressureRange>mmHg for diastolic (<docset:BloodPressureRange>1 </docset:BloodPressureRange>repeat is allowed) as determined by the investigator, or results with unacceptable deviations that are judged by the investigator to be clinically significant for the population, or have a heart rate outside the range of <dgc:TimeDuration>50 </dgc:TimeDuration>to <docset:HeartRateRange>90 beats</docset:HeartRateRange>/minute. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 1858.3; width: 1608.3; height: 282.2; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1858.3; width: 87.5; height: 50.0; page: 28;}; ">

                     [19] </dg:chunk><dg:chunk>have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the IP; or of interfering with the interpretation of data. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 447.0; top: 2179.2; width: 1036.3; height: 50.0; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2179.2; width: 87.5; height: 50.0; page: 28;}; ">

                     [20] </dg:chunk><dg:chunk structure="p">have known or ongoing psychiatric disorders. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 447.0; top: 2266.7; width: 1503.0; height: 108.3; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2266.7; width: 87.5; height: 50.0; page: 28;}; ">

                     [21] </dg:chunk><dg:chunk>regularly use known drugs of abuse and/or show positive findings on urinary drug <dgm:_testRef>screening</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 446.4; top: 2412.5; width: 1599.4; height: 108.3; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2412.5; width: 87.5; height: 50.0; page: 28;}; ">

                     [22] </dg:chunk><dg:chunk>show evidence of an acute <dgm:Condition>infection </dgm:Condition>with fever or infectious disease at the time of <dgm:_testRef>study </dgm:_testRef>entry. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 2558.3; width: 1587.5; height: 111.7; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2558.3; width: 87.5; height: 50.0; page: 28;}; ">

                     [23] </dg:chunk><dg:chunk>show evidence of human <dgm:Condition>immunodeficiency </dgm:Condition>virus (<dgm:Condition>HIV</dgm:Condition>) <dgm:Condition>infection </dgm:Condition>and/or positive human <dgm:Condition>HIV </dgm:Condition>antibodies. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448.0; top: 2708.3; width: 1556.2; height: 220.8; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2708.3; width: 87.5; height: 50.0; page: 28;}; ">

                     [24] </dg:chunk><dg:chunk>show evidence of <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>C </dgm:Condition>and/or positive <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>C </dgm:Condition>antibody (the presence of <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>C </dgm:Condition>antibodies in the setting of normal liver function tests and a negative <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>C </dgm:Condition>polymerase chain reaction are not exclusions). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 449; top: 302; width: 1645.0; height: 172.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 449; top: 302; width: 94; height: 58; page: 29;}; ">

                     [25] </dg:chunk><dg:chunk>show evidence of <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>B </dgm:Condition>and/or positive <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>B </dgm:Condition>surface antigen (the presence of antibodies to the <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>B </dgm:Condition>surface antigen is not an exclusion). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 451; top: 505; width: 950; height: 59; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 451; top: 505; width: 94; height: 59; page: 29;}; ">

                     [26] </dg:chunk><dg:chunk>are women who are pregnant or lactating. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448; top: 598.0; width: 1592; height: 116.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 448; top: 595; width: 98; height: 56; page: 29;}; ">

                     [27] </dg:chunk><dg:chunk>have significant lipohypertrophy in the target abdominal injection area as judged by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 452; top: 744.0; width: 1623; height: 287.9; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 452; top: 742; width: 92; height: 55; page: 29;}; ">

                     [28] </dg:chunk><dg:chunk>have a history of renal impairment (exclusion only if glomerular filtration rate [estimated GFR] &lt;<docset:RenalImpairmentExclusionCriteria>60 </docset:RenalImpairmentExclusionCriteria>mL/<docset:RenalImpairmentExclusion>minute/1.73 </docset:RenalImpairmentExclusion>m2 [GFR is estimated according to the Chronic Kidney Disease Epidemiology Collaboration creatinine equation]), or have a serum creatinine level &gt;<docset:SerumCreatinineLevel>126 </docset:SerumCreatinineLevel>umol/L (male) or <docset:SerumCreatinineLevel>≥111umol</docset:SerumCreatinineLevel>/L (female). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 444; top: 1059.0; width: 1588; height: 179.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 444; top: 1057; width: 103; height: 61; page: 29;}; ">

                     [29] </dg:chunk><dg:chunk>have a history of deep vein <dgm:Condition>thrombosis </dgm:Condition>of the leg or repeated episodes of deep leg vein <dgm:Condition>thrombosis </dgm:Condition>in first-degree relatives (parents, siblings, or children) as judged by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448; top: 1270.0; width: 1628; height: 175.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 448; top: 1269; width: 98; height: 60; page: 29;}; ">

                     [30] </dg:chunk><docset:RetinopathyandNeuropathyCriteria structure="p">have proliferative <dgm:Condition>retinopathy </dgm:Condition>or <dgm:Condition>maculopathy </dgm:Condition>and/or severe <dgm:Condition>neuropathy</dgm:Condition>; in particular, autonomic <dgm:Condition>neuropathy </dgm:Condition>as judged by the investigator based on a recent (&lt;<docset:OphthalmologicExam>1.5 years) </docset:OphthalmologicExam>ophthalmologic <dgm:_testRef>examination </dgm:_testRef></docset:RetinopathyandNeuropathyCriteria></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448; top: 1474.0; width: 1584; height: 115.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 448; top: 1470; width: 96; height: 59; page: 29;}; ">

                     [31] </dg:chunk><dg:chunk>have donated blood of more than <docset:BloodDonationAmount>450 </docset:BloodDonationAmount>mL or more in the last <docset:BloodDonationFrequency>3 months </docset:BloodDonationFrequency>or provided any blood donation within the last month before <dgm:_testRef>screening </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 449; top: 1617; width: 1650; height: 235; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 449; top: 1618; width: 95; height: 57; page: 29;}; ">

                     [32] </dg:chunk><dg:chunk>have a significant history of <dgm:Condition>alcoholism </dgm:Condition>or drug abuse as judged by the investigator or consuming more than <docset:AlcoholConsumption>24 </docset:AlcoholConsumption>g of alcohol per day for men, or more than <docset:AlcoholConsumption>12 </docset:AlcoholConsumption>g of alcohol per day for women (<docset:AlcoholAbuseHistory>1 </docset:AlcoholAbuseHistory>unit of alcohol is defined as <docset:AlcoholConsumption>10 </docset:AlcoholConsumption>mL [8 g] of pure alcohol). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 452; top: 1878; width: 1579; height: 173.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 452; top: 1878; width: 93; height: 55; page: 29;}; ">

                     [33] </dg:chunk><docset:AreUnwilling-section><dg:chunk structure="h1">are unwilling </dg:chunk><docset:AreUnwilling structure="div">to comply with the dietary requirements/restrictions during the <dgm:_testRef>study</dgm:_testRef>: (<docset:DietaryRequirements>1</docset:DietaryRequirements>) comply with the fasting requirements of the <dgm:_testRef>study</dgm:_testRef>, (ii) consume only the meals/snacks provided during the inpatient visits. </docset:AreUnwilling></docset:AreUnwilling-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 449; top: 2085.0; width: 1544; height: 114.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 449; top: 2085; width: 95; height: 54; page: 29;}; ">

                     [34] </dg:chunk><docset:AreCurrently-section><dg:chunk structure="h1">are currently </dg:chunk><docset:AreCurrently structure="div">a smoker as defined as more than <docset:SmokingStatus>5 </docset:SmokingStatus>cigarettes (or <dgm:Medication>nicotine </dgm:Medication>equivalent) per day. </docset:AreCurrently></docset:AreCurrently-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 453; top: 2230; width: 1565; height: 179.0; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 453; top: 2230; width: 91; height: 58; page: 29;}; ">

                     [35] </dg:chunk><docset:AllergyInformation structure="p">have known allergies to <dgm:Medication>treprostinil </dgm:Medication><dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glulisine</dgm:Medication>, <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine</dgm:Medication>, related compounds, or any components of the formulation, or a history of significant atopy. </docset:AllergyInformation></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 447; top: 2434; width: 1645; height: 406; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 447; top: 2434; width: 99; height: 59; page: 29;}; ">

                     [36] </dg:chunk><dg:chunk>have, except for current regimen of <dgm:Medication>insulin </dgm:Medication>therapy and concomitant medication(s) (for example, antihypertensive medication, <dgm:Medication>lipid</dgm:Medication>-lowering agent, <dgm:Medication>thyroid </dgm:Medication>hormone replacement medication, hormonal contraception, hormonal replacement therapy), regular use of or intended use of any over- the-counter or prescription medications or nutritional supplements that treat hyperglycaemia or <dgm:Medication>insulin </dgm:Medication>resistance or that promote weight loss within <docset:MedicationRestriction>14 days </docset:MedicationRestriction>before dosing. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 444; top: 2871; width: 894; height: 64.8; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 444; top: 2871; width: 103; height: 65; page: 29;}; ">

                     [37] </dg:chunk><dg:chunk>are treated with a <docset:InsulinPumpTreatment>CSII </docset:InsulinPumpTreatment>(<dgm:Medication>insulin </dgm:Medication>pump). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566.7; top: 308.3; width: 1512.5; height: 283.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 308.3; width: 83.3; height: 50.0; page: 30;}; ">

                     [38] </dg:chunk><dg:chunk>have regular use of or intended use of known inducers or inhibitors of cytochrome <dg:chunk>P450 </dg:chunk>[<docset:CytochromeP4502C8>CYP]2C8 </docset:CytochromeP4502C8>or <dgm:Medication>niacin</dgm:Medication>. Patients taking these medications before <dgm:_testRef>study </dgm:_testRef>enrollment will be eligible with an appropriate washout period which will be evaluated by the investigator in consultation with the <dg:chunk>Lilly CP</dg:chunk>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 629.2; width: 1612.5; height: 225.0; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 629.2; width: 83.3; height: 50.0; page: 30;}; ">

                     [39] </dg:chunk><dg:chunk>are receiving chronic (lasting longer than <docset:GlucocorticoidTreatmentDuration>14 consecutive days</docset:GlucocorticoidTreatmentDuration>) systemic or inhaled glucocorticoid therapy (excluding topical, intra-articular, and intraocular preparations), or have received such therapy within <docset:GlucocorticoidTherapyWindow>4 weeks </docset:GlucocorticoidTherapyWindow>before <dgm:_testRef>screening</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 891.7; width: 1575.0; height: 166.7; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 891.7; width: 83.3; height: 50.0; page: 30;}; ">

                     [40] </dg:chunk><dg:chunk>any significant changes in <dgm:Medication>insulin </dgm:Medication>regimen and/or unstable blood glucose control within the past <docset:InsulinRegimenStability>3 months </docset:InsulinRegimenStability>prior to <dgm:_testRef>screening </dgm:_testRef>as assessed by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1095.8; width: 1416.7; height: 108.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 1095.8; width: 83.3; height: 50.0; page: 30;}; ">

                     [41] </dg:chunk><docset:DulaglutideTreatment structure="p">currently receiving <dgm:Medication>dulaglutide </dgm:Medication>therapy or have been treated with <dgm:Medication>dulaglutide </dgm:Medication>within the past <docset:TreatmentWindow>30 days</docset:TreatmentWindow>. </docset:DulaglutideTreatment></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 447.0; top: 1241.7; width: 1215.5; height: 50.0; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1241.7; width: 87.5; height: 50.0; page: 30;}; ">

                     [42] </dg:chunk><dg:chunk>require <dgc:Frequency>daily </dgc:Frequency><dgm:Medication>insulin </dgm:Medication>treatment &gt;<docset:InsulinDose>1.2 </docset:InsulinDose>U/kg/body weight. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 1329.2; width: 1620.8; height: 108.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1329.2; width: 87.5; height: 50.0; page: 30;}; ">

                     [43] </dg:chunk><dg:chunk>in the opinion of the investigator or sponsor, are unsuitable for inclusion in the <dgm:_testRef>study</dgm:_testRef>. </dg:chunk></dg:chunk></docset:StudyExclusionCriteria><docset:StudyDrugAdministration structure="ol" style="list-style-type: decimal; boundingBox:{left: 295.8; top: 1508.3; width: 1708.3; height: 1208.3; page: 30;}; boundingBox:{left: 295.8; top: 325.0; width: 1058.3; height: 1866.7; page: 31;}; "><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 1508.3; width: 1912.5; height: 1083.1; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295.8; top: 1508.3; width: 145.8; height: 58.3; page: 30;}; ">

              6.2.1. </dg:chunk><docset:AdditionalExclusionCriteriaforInpatientDosingDays-section><dg:chunk structure="h1"><dg:chunk>Additional Exclusion Criteria </dg:chunk>for <dg:chunk>Inpatient Dosing Days </dg:chunk></dg:chunk><docset:AdditionalExclusionCriteriaforInpatientDosingDays structure="div"><docset:InpatientDosing-DayExclusionCriteria structure="p">                  Patients who fulfil <docset:InpatientExclusionCriteria>1 </docset:InpatientExclusionCriteria>or more inpatient dosing-day exclusion criteria will be excluded from <dgm:_testRef>study </dgm:_testRef>drug administration for that MMTT day. A single inpatient trial period can be rescheduled <dgc:Number>1 </dgc:Number>to <docset:ReschedulePeriod>14 days </docset:ReschedulePeriod>later. Each treatment period can only be rescheduled once.                   The following exclusion criteria apply to the day before each MMTT day: </docset:InpatientDosing-DayExclusionCriteria><docset:ExclusionCriteria structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 445.8; top: 1870.8; width: 1762.5; height: 720.6; page: 30;}; "><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 1870.8; width: 566.7; height: 50.0; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1870.8; width: 87.5; height: 50.0; page: 30;}; ">

                     [44] </dg:chunk><dg:chunk>positive drug <dgm:_testRef>screen</dgm:_testRef>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 1958.3; width: 1345.8; height: 50.0; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1958.3; width: 87.5; height: 50.0; page: 30;}; ">

                     [45] </dg:chunk><dg:chunk>positive <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>administered on Day <docset:DayofPregnancyTest>-1 </docset:DayofPregnancyTest>of Period 1. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 2045.8; width: 1700.0; height: 108.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2045.8; width: 87.5; height: 50.0; page: 30;}; ">

                     [46] </dg:chunk><dg:chunk>any medical condition or AE that could interfere with glucose metabolism, as judged by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 445.8; top: 2191.7; width: 1695.8; height: 108.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2191.7; width: 87.5; height: 50.0; page: 30;}; ">

                     [47] </dg:chunk><dg:chunk>any use of prescription or nonprescription medication according to <dg:chunk>Exclusion Criteria </dg:chunk>[<docset:PrescriptionMedicationUse>36</docset:PrescriptionMedicationUse>], [<docset:MedicationUse>39</docset:MedicationUse>] and [<docset:MedicationUse>41</docset:MedicationUse>]. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 446.0; top: 2337.5; width: 1733.2; height: 108.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2337.5; width: 87.5; height: 50.0; page: 30;}; ">

                     [48] </dg:chunk><dg:chunk><dgm:Condition>hypoglycemia </dgm:Condition>during the treatment period and less than <docset:HypoglycemiaRiskPeriod>24 hours </docset:HypoglycemiaRiskPeriod>before dosing that poses a significant risk to patient safety, as judged by the investigator. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 446.0; top: 2483.3; width: 1762.3; height: 108.1; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 2483.3; width: 87.5; height: 50.0; page: 30;}; ">

                     [49] </dg:chunk><dg:chunk>injection of a bolus of more than <docset:InsulinBolus>6 </docset:InsulinBolus>U of a fast-acting <dgm:Medication>insulin </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>) between <docset:InsulinBolusTiming>7 and </docset:InsulinBolusTiming><docset:InsulinBolusTiming>12 hours </docset:InsulinBolusTiming>before <dgm:_testRef>test </dgm:_testRef>meal. </dg:chunk></dg:chunk></docset:ExclusionCriteria></docset:AdditionalExclusionCriteriaforInpatientDosingDays></docset:AdditionalExclusionCriteriaforInpatientDosingDays-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 2662.5; width: 1945.8; height: 183.3; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295.8; top: 2662.5; width: 100.0; height: 54.2; page: 30;}; ">

              6.3. </dg:chunk><docset:LifestyleAndOrDietaryRequirements-section><dg:chunk structure="h1">Lifestyle and/or Dietary Requirements </dg:chunk><docset:LifestyleAndOrDietaryRequirements structure="div">              Throughout the <dgm:_testRef>study</dgm:_testRef>, patients may undergo medical assessments and review of compliance with requirements before continuing in the <dgm:_testRef>study</dgm:_testRef>. </docset:LifestyleAndOrDietaryRequirements></docset:LifestyleAndOrDietaryRequirements-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 325.0; width: 1937.5; height: 676.0; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 325.0; width: 141.7; height: 58.3; page: 31;}; ">

              6.3.1. </dg:chunk><docset:MealsAndDietaryRestrictions-section><dg:chunk structure="h1">Meals and <dg:chunk>Dietary Restrictions </dg:chunk></dg:chunk><docset:MealsAndDietaryRestrictions structure="div">              Patients will be fasted (except for water) for at least <docset:FastingPeriod>10 hours </docset:FastingPeriod>before each <dgm:_testRef>test </dgm:_testRef>meal and <docset:FastingPeriod>8 hours </docset:FastingPeriod>prior to <dgm:_testRef>screening </dgm:_testRef>and follow-up assessments (see Section 9.5.8 for guidelines on <dgm:Condition>hypoglycemia </dgm:Condition>treatment). The patient will not be allowed to consume water for <docset:NoWaterConsumption>2 hours </docset:NoWaterConsumption>after the MMTT assessment begins; however, water may be consumed freely <dgc:TimeDuration>2 hours </dgc:TimeDuration>postmeal.               While resident in the CRU, patients may not consume any food or caloric drinks other than that provided by the CRU. When not resident in the CRU, patients may resume their regular diet and should not make major changes to the dietary habits during the <dgm:_testRef>study</dgm:_testRef>.               Following completion of <dgm:_testRef>study </dgm:_testRef>procedures, patients will be offered a meal. Site will record dose and time of prandial <dgm:Medication>Humalog </dgm:Medication>administered with end-of-<dgm:_testRef>study </dgm:_testRef>meal. </docset:MealsAndDietaryRestrictions></docset:MealsAndDietaryRestrictions-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 1070.8; width: 1950.0; height: 620.8; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295.8; top: 1070.8; width: 145.8; height: 58.3; page: 31;}; ">

              6.3.2. </dg:chunk><docset:CaffeineAlcoholAndTobacco-section><dg:chunk structure="h1"><dgm:Medication>Caffeine</dgm:Medication>, Alcohol, and Tobacco </dg:chunk><docset:CaffeineAlcoholAndTobacco structure="div">              Patients should refrain from <dgm:Medication>caffeine</dgm:Medication>-containing food/beverages (for example, cola, chocolate drinks, tea, coffee, energy drinks containing methylxanthine [<dgm:Medication>caffeine</dgm:Medication>, <dgm:Medication>theophylline</dgm:Medication>, or theobromine]) for at least <docset:CaffeineRestriction>12 hours </docset:CaffeineRestriction>before each <dgm:_testRef>test </dgm:_testRef>meal and throughout the duration of each CRU visit.               No alcohol will be allowed at least <docset:AlcoholandCaffeineRestrictions>24 hours </docset:AlcoholandCaffeineRestrictions>before each CRU admission (Day –1) and throughout the duration of each CRU visit. Between CRU visits, <dgc:Frequency>daily </dgc:Frequency>alcohol should not exceed <docset:AlcoholandCaffeineRestrictions>3 </docset:AlcoholandCaffeineRestrictions>units for males and <docset:AlcoholRestrictions>2 </docset:AlcoholRestrictions>units for females (see Section 6.2, #<docset:AlcoholandCaffeineRestrictions>32 </docset:AlcoholandCaffeineRestrictions>for unit definition).               No cigarette smoking will be permitted during the <dgm:_testRef>study</dgm:_testRef>. </docset:CaffeineAlcoholAndTobacco></docset:CaffeineAlcoholAndTobacco-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1758.3; width: 1912.5; height: 307.7; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1758.3; width: 141.7; height: 58.3; page: 31;}; ">

              6.3.3. </dg:chunk><docset:Activity-section><dg:chunk structure="h1">Activity </dg:chunk><docset:Activity structure="div">              Patients will be encouraged to maintain their regular exercise and <dgm:Medication>insulin </dgm:Medication>regimen adaptation related to exercise during the outpatient period; however, they should not undertake vigorous or prolonged exercise at least <docset:ExerciseRestriction>24 hours </docset:ExerciseRestriction>before each dosing day at the CRU. Movement will be restricted to retain the integrity of connections to infusion(s) and the <dgm:_testRef>study </dgm:_testRef>procedures. </docset:Activity></docset:Activity-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 2133.3; width: 579.2; height: 58.3; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 2133.3; width: 95.8; height: 58.3; page: 31;}; ">

              6.4. </dg:chunk><dg:chunk structure="h1"><dgm:_testRef>Screen </dgm:_testRef>Failures </dg:chunk></dg:chunk></docset:StudyDrugAdministration></dg:chunk></dg:chunk><docset:ParticipationCriteria structure="p">

              Individuals who do not meet the criteria for participation in this <dgm:_testRef>study </dgm:_testRef>may not be rescreened.</docset:ParticipationCriteria></dg:chunk></dg:chunk></docset:FollowingInsulin></docset:FollowingInsulin-section></docset:FigureITRW1></docset:FigureITRW1-section></docset:PatientswithT2DM></docset:PatientswithT2DM-section></dg:chunk>